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Due to the ageing population, the rate of the eye diseases has increased globally. Thus, 
there is a great need to develop more effective ophthalmic drugs and dosing methods. 
Ocular diseases are often treated with eye-drops or ointments. However, typically less 
than 5 % of the drug reaches the target tissue, since major part of the dose is 
systemically absorbed via nasolacrimal system. The main barrier for ocular absorption 
is the tightness of corneal epithelium, the outer most layer of the eye. In addition, the 
sensitivity of the eye presents challenges for the development of the optimal ophthalmic 
formulations. 
Drug discovery and development is an economically risky and long lasting 
process. It takes an average of 10-15 years before a new drug is available to the patients. 
Even today, drug development relies heavily on animal testing so there is pressure to 
develop ethically more acceptable methods to replace or support animal testing. 
Especially in the early stages of drug development in silico computational and 
computer-based methods are widely used for mapping new potential drug molecules. In 
addition, simple physicochemical properties such as lipophilicity, ionization and 
solubility can be measured to predict how the drug is absorbed, distributed and excreted 
from the body. Absorption processes can also be modelled by various in vitro cell 
models and artificial lipid membranes. These methods can be used to select the most 
potential drug candidates for further animal studies and clinical trials on humans. 
In this thesis, it was studied if the Quality Control and Analytical Development 
Laboratory of Santen Oy could utilize HPLC instruments and simple shake-flask 
method in modelling the factors affecting lipophilicity of the ophthalmic drugs and 
hence predict their absorption potential. Lipophilicity of two commercial isopropyl ester 
prodrugs and their biologically active metabolites were studied by C18-HPLC over a 
wide pH range to obtain pH-lipophilicity profiles. Moreover, it was studied if some 
specific interactions between these drug molecules and a certain drug additive could be 
revealed. The ion-pair formation between a common anti-glaucoma drug timolol and a 
sorbate additive was verified as increased lipophilicity by this method. In addition, a 
modified shake-flask method was developed for determining the octanol-water partition 
coefficients of drugs. 
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Väestön ikääntymisen johdosta silmäsairaudet ovat yleistyneet, joten tarve kehittää 
tehokkaampia silmälääkkeitä ja toimivampia annostelutapoja on suuri. Silmäsairauksien 
hoidossa käytetään useimmiten silmän pinnalle annosteltavia silmätippoja tai -voiteita, 
joista imeytyy silmään tyypillisesti alle 5 %. Iso osa lääkkeestä kulkeutuu annostelun 
jälkeen kyynelkanavia pitkin nenänielun limakalvoille ja imeytyy systeemiseen 
verenkiertoon. Lääkeaineen imeytymistä rajoittaa erityisesti silmän pinnan 
sarveiskalvon tiivis epiteelisolukko. Lisäksi silmän herkkyys asettaa omat haasteensa 
optimaalisten lääkeformulaatioiden kehitykselle. 
Lääketutkimus- ja kehitystyö on hidas ja taloudellisesti riskialtis prosessi. Uuden 
lääkkeen kehitys ja pääsy potilaskäyttöön vie keskimäärin jopa noin 10-15 vuotta. Vielä 
tänäkin päivänä tutkimuksissa käytetään runsaasti eläinkokeita, joten paine kehittää 
eläinkokeita korvaavia tai täydentäviä eettisesti hyväksyttävämpiä tutkimusmenetelmiä 
on suuri. Erityisesti lääkekehityksen alkuvaiheessa käytetään nykyään laajalti erilaisia 
laskennallisia ja tietokonepohjaisia menetelmiä potentiaalisten lääkeainemolekyylien 
kartoittamiseksi. Lisäksi yksinkertaisten fysikaaliskemiallisten ominaisuuksien, kuten 
dissosioitumisasteen sekä rasva- ja vesiliukoisuuden kartoittamisen avulla voidaan tehdä 
oletuksia siitä, miten lääke imeytyy, jakautuu ja erittyy elimistössä.  Imeytymistä 
voidaan mallintaa myös erilaisten in vitro solumallien ja keinotekoisten lipidikalvojen 
avulla. Nämä menetelmät auttavat seulomaan potentiaalisimmat lääkekandidaatit 
jatkossa tehtäviin eläin- ja ihmiskokeisiin. 
Tässä työssä tutkittiin, miten Santen Oy:n laadunvalvonta- ja analytiikan 
kehityslaboratoriossa voitaisiin HPLC-laitteistojen ja ravistelukokeiden avulla mallintaa 
lääkeaineiden rasvaliukoisuuteen vaikuttavia tekijöitä ja siten ennustaa lääkeaineen 
kykyä imeytyä silmään. Lääkeformuloinnissa käytettävän pH:n ja erään apuaineen 
vaikutusta kahden kaupallisen aihiosilmälääkkeen ja näiden biologisesti aktiivisten 
hajoamistuotteiden rasvaliukoisuuteen tutkittiin C18-HPLC laitteiston avulla. 
Menetelmän avulla onnistuttiin myös havainnollistamaan, kuinka sorbaattiapuaine lisää 
glaukooman hoidossa yleisesti käytetyn timololin rasvaliukoisuutta ionipariutumisen 
vuoksi. Lisäksi työssä kehitettiin yksinkertainen ravistelukoemenetelmä, jolla voidaan 
määrittää lääkeaineiden rasvaliukoisuutta oktanoli-vesi-jaukautumiskertoimien avulla. 
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1. INTRODUCTION 
Drug discovery and development is expensive and long lasting process which takes an 
average of 10-15 years (Rang & Hill 2012). Usually it includes drug discovery, product 
development, pre-clinical research and clinical trials on humans (Gad 2005). Speeding 
up drug discovery and development processes requires more effective and reliable 
research tools (Kraljevic et al. 2004). Even today, drug development relies heavily on 
animal testing so there is pressure to develop and apply ethically more acceptable 
methods (Badyal & Desai 2014). Especially in the early stages of drug development in 
silico computational and computer-based methods can be used for mapping new 
potential drug molecules (Ekins et al. 2007). In addition, simple physicochemical 
properties such as lipophilicity, ionization and solubility can be measured to predict 
how the drug is absorbed, distributed and excreted from the body (Henchoz et al. 2009). 
Absorption processes can also be modelled by various in vitro cell models and artificial 
lipid membranes (Agarwal & Rupenthal 2016; Kansy et al. 1998). These methods can 
be used to select the most potential drug candidates for further animal studies and 
clinical trials on humans. (Vellonen 2010) 
 
Due to the ageing population, the rate of the eye diseases has increased globally 
(Flaxman et al. 2017). Thus, there is a great need to develop more effective ophthalmic 
drugs and dosing methods. Ocular diseases are often treated with eye-drops or 
ointments. However the target tissues for most ophthalmic drugs are located in the inner 
eye and typically less than 5 % of the drug reaches the site of action. The main barrier 
for ocular absorption is the tightness of corneal epithelium, but also systemic absorption 
from the conjunctiva and rapid elimination process by tear turnover limit the 
bioavailability of the ophthalmic drugs. Formulation researchers have traditionally tried 
to enhance ocular absorption either by increasing the permeability of the drug or by 
prolonging its corneal contact time. (Järvinen et al. 1995; Furrer et al. 2008) Contact 
time can be prolonged for example by increasing the viscosity of the drugs or by solid 
drug-releasing inserts, which unfortunately give patients a sensation of a foreign body in 
the eye (Furrer et al. 2008). In addition, drug permeability can be enhanced by chancing 
pH or osmolality of the drug solution, by using penetration enhancers and high 
permeability prodrugs or by encapsulating drugs into nanoparticles and liposomes 
(Furrer et al. 2008; Xu et al. 2013). The sensitivity of the eye presents challenges for the 
development of the optimal ophthalmic formulations, because if the formulation causes 
discomfort, enhanced lacrimation increases the drug loss (Furrer et al. 2008). 
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Literature review of this thesis is aimed at employees with non-pharmaceutical 
education background starting their work in ophthalmic drug development. The thesis 
presents the factors that affect the absorption of drugs, especially ophthalmic drugs. In 
addition, various models for drug permeation studies are introduced. The emphasis is on 
the determination of physicochemical properties such as lipophilicity and ionization 
constant. Lastly, liquid chromatography methods for pharmaceutical permeation studies 
are summarized. 
 
Experimental part of the thesis was performed in the Quality Control and Analytical 
Development Laboratory of Santen Oy. The aim of the study was to develop in-house 
physicochemical laboratory models to support ophthalmic formulation development at 
Santen Oy. The main idea for experimental study was to find out if common RP-HPLC 
instruments and simple shake-flask method could be utilized in modelling the 
lipophilicity of the ophthalmic drugs. The first goal was to find out how the effect of the 
formulation pH could be studied by HPLC. Another aim was to test whether the HPLC 
measurements or shake-flask method could reveal drug-additive interaction. 
 
Experimental part is divided into three different chapters. In the first chapter, 
lipophilicity of two commercial isopropyl ester prodrugs and their biologically active 
metabolites are studied by HPLC. For each compound, lipophilicity expressed as log k, 
is measured over a wide pH range to obtain pH-lipophilicity profiles which could be 
utilized while choosing the optimal formulation pH. Moreover, it is studied if some 
specific interactions, such as ion pairing between these drug molecules and a certain 
drug additive could be revealed with a C18-HPLC-system by adding increasing amount 
of the additive into the eluent. In the second chapter, a modified shake-flask method is 
set up for determining direct log Pow values of drugs at Santen Oy.  Lipophilicity (log 
Pow) of an isopropyl ester prodrug with and without additive molecules is directly 
measured by this method in order to compare results obtained in previous chapter by 
RP-HPLC method. In the third chapter, the C18-HPLC method for studying drug-
additive interactions is validated by using common anti-glaucoma drug timolol and a 
sorbate additive, for which ion pairing had been previously verified by NMR 
(Higashiyama et al. 2007). Before ion pairing studies, the eluent composition was 
optimized for timolol. Additionally, the pH-lipophilicity profile of timolol is measured. 
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2. DRUG ABSORPTION 
Whatever the route of drug administration (e.g. parenteral, oral, percutaneous, 
pulmonary, ocular), drug must usually pass through at least one body membrane before 
reaching the target receptor. This movement is called absorption. Membranes are 
biological barriers that selectively inhibit the passage of drug molecules. Rate of the 
absorption depends both on the physicochemical properties of the drug and the 
membrane properties (Seydel & Wiese 2002). 
2.1. Structure and lipid composition of cell membranes 
Cell membranes are composed primarily of lipid bilayer. Membranes also contain 
embedded membrane proteins, cholesterol and oligosaccharide chains on the cell 
membrane surface (Figure 1). Although the lipid layer is highly organized it behaves as 
a dynamic fluid. According to the fluid mosaic model the biological membranes behave 
as two-dimensional liquid where phospholipids are able to move in the lateral plane of 
the bilayer. (Singer et al. 1972) 
 
 
 
 
 
 
Figure 1. Simplified schematic presentation of an animal cell membrane (modified from 
ref. Stern 1996). 
 
oligosaccharides 
lipid 
bilayer 
proteins 
cholesterol 
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Lipid and protein composition of mammalian membranes varies in different species and 
organs. Therefore drug distribution and accumulation is cell organelle dependent. The 
common building blocks of lipid bilayer are however universal. There are three main 
classes of membrane lipids: phospholipids, glycolipids, and cholesterol. Phospholipids, 
the major component of cell membranes, can be further subdivided into 
glycerophospholipids and sphingosine-containing phospholipids. Most phospholipids 
have a glycerol backbone. These glycerophospholipids consist of two long-chain fatty 
acids which are esterified with hydroxyl groups of glycerol. The remaining hydroxyl 
group of glycerol is esterified to phosphoric acid which is further substituted by some 
sugar or amino alcohol such as choline, serine or ethanolamine. (Seydel & Wiese 2002; 
McGraw-Hill 1982) 
 
 
 
Figure 2. Classification and the structural formulas of the most common amphipathic 
membrane lipids. (Wikipedia 2018) 
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Sphingolipids are derived from sphingosine instead of glycerol. All sphingolipids have 
a ceramide backbone in which a fatty acid chain is attached to amino alcohol 
sphingosine by an amide linkage. Sphingomyelins are the only sphingolipid class that 
belongs also to phospholipids. Sphingomyelins have a phosphocholine or 
phosphoethanolamine molecule esterified to the 1-hydroxy group of a ceramide.  
(Seydel & Wiese 2002; McGraw-Hill 1982) Glycolipids contain one or more 
monosaccharide residues bound by a glycosidic linkage to a hydrophobic moiety such 
as an acylglycerol, a sphingoid, a ceramide or a prenyl phosphate (Chester 1997). 
 
Most membrane lipids are amphipathic. The polar head groups and phosphate groups 
are hydrophilic, whereas non-polar fatty acid moieties are lipophilic. Thus, 
phospholipids are likely to spontaneous form bilayers in water. The hydrophobic fatty 
acids tails are facing each other and the hydrophilic polar head groups are exposed to 
the surrounding aqueous medium. Compared to the other membrane lipids, cholesterol 
is only weakly amphipathic since it has a single hydroxyl group (Figure 3). Therefore it 
is located in the hydrophobic region of the lipid bilayer. The increase of cholesterol 
restricts the mobility of membrane due to the rigid steroid ring structure. (Seydel & 
Wiese 2002) 
 
 
Figure 3. The structural formula of cholesterol. 
2.2. Drug absorption across biological membranes 
Drugs can be absorbed across any epithelial cell layer by two principal routes, 
transcellular or paracellular (Figure 4). In paracellular route drugs are transported 
between cells via water-filled intercellular junctions, whereas in the transcellular route 
drugs must pass first through the apical membrane, then across cytoplasm and finally 
through the basolateral membrane. Lipophilic drugs prefer the transcellular route 
because of the lipidic nature of cell membrane, while the paracellular route is preferred 
by hydrophilic drugs. (Bermejo 2008) The major barrier in the paracellular route is the 
tight junction located between the epithelial cells. The tightness, ion selectivity and 
number of these junctions vary among epithelia significantly. (Anderson 2001) 
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Figure 4. Transepithelial transport pathways (Anderson 2001). 
 
Transcellular absorption can be divided into passive diffusion and carrier mediated 
transport mechanisms, such as facilitated diffusion and active transport (Figure 5). 
Facilitated diffusion is a movement of drug molecules down a concentration gradient 
via special transport proteins. It does not require external energy unlike active transport 
in which drugs can be transported against concentration gradient. Since these transport 
mechanisms are mediated by transporter proteins, the extent of facilitated diffusion and 
active transport is highly depended on the binding affinity between the drug and the 
protein. Carrier mediated transportation is therefore very selective and saturates easily 
since at high concentration levels all carrier proteins are occupied. (Bermejo 2008) 
 
 
 
 
Figure 5. Different transcellular absorption mechanisms across cell membrane. (van 
Balen et al. 2004) 
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The predominant absorption route for drug compounds is passive transcellular diffusion. 
This absorption route requires that the compound can first leave behind the surrounding 
water molecules, pass the polar head groups of lipids, permeate through the lipophilic 
membrane interior, and then enter again to the hydrophilic surroundings on the other 
side of the membrane. Passive transcellular diffusion is driven by a concentration 
gradient from a region of high concentration to a region of relatively lower 
concentration. (Kerns 2001)  Amount of drug diffused across a membrane in certain 
time depends on the permeability of the drug and the concentration gradient across the 
membrane. Maximal drug absorption is achieved when the drug has optimal 
permeability and maximum concentration at the site of absorption. Mathematically drug 
flux across the membrane can be expressed by Fick’s first law. When assuming that the 
concentration gradient across membrane is time-independent and linear, Fick’s law can 
be simplified into following equation: 
 
cPJ Δ=           (1) 
 
where J is the drug flux across membrane per area unit per time unit, P is permeability 
coefficient and the Δc is the concentration gradient. Permeability coefficient can be 
further described by equation: 
 
h
DKP =          (2) 
 
where D is the diffusion coefficient of the drug within the membrane, K is the partition 
coefficient of the drug into the membrane and the h is the effective thickness of 
diffusion barrier i.e. membrane. (Loftsson et al. 2006; Brodin 2010) Partition coefficient 
is generally denoted also by symbol P, but in this context symbol K is chosen to avoid 
confusion with permeability. 
 
Although membrane is the main barrier for most drugs, stagnant water layer adjacent to 
the membrane surface can behave as a diffusion barrier for drugs that readily permeate 
the lipidic membrane. The significance of this aqueous barrier depends on the 
absorption route.  For example at skin surface the aqueous layer is usually very thin and 
therefore relatively insignificant for the overall absorption process. However, mucin 
layer on the surface of the eye or intestinal epithelium can significantly affect the 
overall diffusion barrier. Thus drugs must be hydrophilic enough to diffuse through the 
membrane covering water layer and lipophilic enough to be able to partition from the 
aqueous surface into the membrane.  (Loftsson et al. 2006) 
 
In addition to water solubility and lipophilicity, there are several physicochemical 
properties of drugs, such as charge, the degree of ionization, molecular size and shape, 
hydrogen bonding capacity and polar surface are, which have an effect on permeation 
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through biological membranes. These properties are discussed more detailed in next 
chapter. 
 
Yet another factor to consider is the protein binding affinity of drugs. Some drug 
molecules may have tendency to bind to plasma or tissue proteins. Bound drug is mostly 
pharmacologically inactive, but since such a binding is usually reversible, proteins can 
act as a reservoir of drugs. However, only free drug molecule is capable of diffusing 
through the membrane. (Schmidt et al. 2010) 
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3. PHYSICOCHEMICAL PROPERTIES 
DETERMINING MEMBRANE PERMEATION 
3.1. Molecular size and weight  
Drug absorption is highly dependent on molecular size which can be estimated by 
molecular weight. Especially in paracellular route diffusion rates are limited by molar 
mass. The larger the molecular mass, the slower the diffusion. (Bermejo 2008) For 
example, corneal epithelium allows paracellular permeation of only small molecules. 
Molecular size 500 g/mol has been estimated to be the upper limit. Conjunctiva is 
however leakier due to larger intercellular pore sizes and higher pore density. 
Paracellular space of conjunctiva allows permeation of molecules which molecular mass 
range between 5 000 and 10 000 g/mol. (Hämäläinen et al. 1997a) However, for larger 
molecules other absorption routes such as facilitated diffusion or active transportation 
by endocytosis are still possible. (Bermejo 2008) 
3.2. Ionization and charge 
Many drugs are either weak organic acids, bases or their salts. In aqueous solutions 
weak electrolytes exist as in ionized or in molecular (non-ionized) form. The degree of 
ionization of these drugs in solutions is extremely dependent on the ionization constant 
(pKa) of the molecule and the pH of the environment. Exceptions to this generalization 
are steroids and quaternary ammonium compounds, which dissociate completely at 
physiological pH values and behave as strong electrolytes. (Gynther et al. 2003) 
 
For weak acids the relationship between ionization constant pKa and pH value can be 
presented by Henderson-Hasselbalch equation: 
 
[ ]
[ ]HA
ApKpH a
−
+= log        (3) 
 
where [A-] represents the concentration of deprotonated  form and [HA] the 
concentration of protonated form of the acid. Equation 3 illustrates that when pH is 
equal to the pKa of the acid, there are present equal amount of protonated and 
deprotonated acid molecules. Decrease in pH value increases the amount of non-ionized 
form of the acid. Thus the lower the pKa value of the drug is the stronger the acid is. 
(Gynther et al. 2003) 
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The same Henderson-Hasselbalch relationship holds for weak bases as well: 
 
[ ]
[ ]++= BH
BpKpH a log        (4) 
 
When pH of the solution decreases, also the amount of non-ionized form of the weak 
base decreases. (Gynther et al. 2003) 
 
 
 
Figure 6. Percentage of non-ionized drug as a function of pH for weak electrolytes 
having same pKa values. When the pH is greater than the pKa of an acidic drug the drug 
will be ionized. Conversely basic drugs will be ionized when the pH is lower than the 
drug's pKa. (Crespo 2010) 
 
Situation is however more complicated when a drug has more than one acidic or basic 
center. Ampholytes for example can exist in acidic, basic, neutral or zwitterionic form 
depending on the pKa values of both acidic and basic center. (Gynther et al. 2003) 
 
According to the pH-partition theory, only the neutral form of the compound can 
permeate through the membrane. Conversely drugs are typically much more water 
soluble in their ionized form. (Gynther et al. 2003) Highly charged nature of cell 
membranes however complicates the situation. Most biological membranes contain 
lipids having acidic and zwitterionic head groups. Thus, the net charge of membrane 
surface is negative on both inner and outer surfaces of the cell. Negative surface 
potential attracts positive counterions from the surrounding solution to the interface 
which creates an electrical double layer adjacent to the membrane. Since surface 
potential increases the surface concentration of cations, they should permeate the 
membrane more readily than the anions. However on membrane-water interface lipid 
bilayer possess a membrane dipole potential that is positive in direction of the 
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membrane interior. This makes the interior of the bilayer more permeable to anions than 
cations, respectively. The origin of dipole potential is not entirely understood, but it has 
been assumed that it arises from the orientation of lipid head groups and the polarized 
water adjacent to the membrane surface. Additionally if there is a concentration 
difference of the ions between both sides of the membrane it will generate a 
transmembrane potential that carries ions along electrochemical gradient. (Mälkiä et al. 
2004) 
3.3. Lipophilicity and partition coefficient (log P) 
 
As a measure of drug permeation in biological membranes, lipophilicity is one of the 
most important physicochemical parameters in predicting and interpreting membrane 
permeability. (Testa et al 1996) Lipophilicity represents the affinity of molecule or a 
moiety for a lipidic environment (van de Waterbeemd et al. 1997). Lipophilicity of a 
drug is usually expressed as log P, the logarithm of partition coefficient between two 
immiscible solvents, an organic and an aqueous phase:  
 
w
o
c
cP loglog =         (5)  
 
where co and cw represent the concentrations of the drug in organic and aqueous phase 
respectively. The greater the value of the partition coefficient is the more lipophilic the 
drug is. Partition coefficients are expressed as in logarithmic scale because of the broad 
range of variation (P = 0,0001-100 000). N-octanol and aqueous buffer solutions are 
most often used as solvents. (Gynther et al. 2003) 
 
Partition coefficient is defined only for neutral (non-ionized) molecules. Many drugs are 
however weak electrolytes, as described earlier, and may be partially ionized depending 
of the pH. Since neutral and ionized molecules exhibit different polarities, their 
lipophilicities are also dissimilar. Thus the partition between organic and aqueous phase 
is pH dependent. When more than one electrical species are present in solution, log P is 
replaced by log D called distribution coefficient (also denoted as an apparent partition 
coefficient log Papp). Log D takes into account the intrinsic lipophilicity of electrical 
species present and their relative concentrations: 
 
[ ] [ ]
[ ] [ ]ww
oo
ionizedneutral
ionizedneutralD
+
+
= loglog       (6) 
(Kah & Brown 2008) 
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If the pKa value of the drug and the pH of the aqueous phase are known, partition 
coefficient can be calculated from distribution coefficient: 
 
For monoprotic weak acids:  


+
−=
− pKapHDP 101
1logloglog    (7) 
For monoprotic weak bases: 


+
−=
− pHpKaDP 101
1logloglog     (8) 
(Gynther et al. 2003) 
 
On the other hand the effective lipophilicity log D of an acidic or basic compound at 
any pH value can be predicted if the dissociation constant pKa and and partitition 
coefficient log P are known. For compounds having more than one ionizable group the 
relationship between log P and log D is obviously much more complex. (Smith et al. 
2001) 
 
Log P and log D values can be used to predict how likely drug candidates permeate cell 
membranes by transcellular passive diffusion. For drugs which permeate though the 
membranes by passive diffusion, the relationship between lipophilicity (log P or log D) 
and permeability is usually bell shaped. Drugs should not be too lipophililic but not too 
hydrophilic either. (Balimane et al. 2000) 
3.4. Hydrogen bonding property and polar surface area 
The surface of the cell membranes provides a finite amount of hydrogen bonding 
groups. Especially polar phospholipid head groups are excellent hydrogen bonding 
acceptors. Before partitioning into the non-polar interior of the lipid bilayer, a drug must 
break the hydrogen bonds with the surrounding water molecules and the polar head 
groups of membrane lipids. Breaking the bonds requires energy and therefore drugs 
must be lipophilic enough to overcome these energy losses. For drugs, which behave as 
strong hydrogen bonding donors, this can be rate limiting step in absorption process. 
Hence, high hydrogen bonding capacity has a negative effect on biological permeation. 
(Mälkiä et al. 2004) 
The polar surface area (PSA) of a molecule characterizes the area of the polar part of the 
molecule. It is defined as a sum of the surface of all polar atoms, primarily oxygen and 
nitrogen, including also their attached hydrogens. PSA is a commonly used in medicinal 
chemistry to estimate drug's ability to permeate cell membranes, since it is easy to 
calculate and it takes into account those drug properties that has an important role in 
membrane permeation such as H-bonding features, molecular polarity and solubility. 
Molecules with a polar surface area of greater than 140 Å2 permeate poorly cell 
membranes due to high polarity. (Mannhold et al. 2007) 
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3.5. Solubility 
Solubility, or rather aqueous solubility is a major problem for drug formulation 
scientists, since nowadays many developed drugs are completely insoluble in water.   
Drug absorption process however requires drugs to be present in the form of solution at 
the site of absorption. Poorly soluble drugs can be modified by various methods to 
improve the solubility. For example in nanosuspensions particle size has been reduced 
to increase the surface area. Crystal engineering can be used to design crystallization 
conditions which affect the particle size, and thus, solubility as well. Solubility can be 
enhanced also by chemical methods such as ion-pair formation, complexation, the use 
of soluble prodrug or surfactants, or changing a pH by buffers. (Savjani et al. 2012) 
 
In addition to the aqueous solubility measurements, nowadays it is more common to 
measure drug dissolution rates also in specific biological fluid compositions. Different 
kind of biorelevant media which can simulate the gastric, intestinal and colonic fluids 
has been developed and commercialized. (Bou-Chacra et al. 2017) Moreover simulated 
saliva, lung fluid, vaginal fluid, semen solutions, tears and sweat have been studied. 
(Marques et al. 2011) 
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4. OCULAR ABSORPTION 
4.1. Anatomy of the eye 
The main analytic elements of human eye are presented in Figure 7. Eye consists of an 
anterior and a posterior segment. Cornea, anterior chamber filled with aqueous humor, 
lens, iris and ciliary body belong to the anterior segment. The posterior segment consists 
of vitreous humor surrounded by retina, choroid, sclera and conjunctiva. Optic nerve 
conducts visual information from the retina to the brain. (Ahmed 2003) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The main analytic elements of human eye and schematic presentation of the 
cross section of cornea. Modified from ref. (Furrer et al. 2008; Smith et al. 2007).  
4.2. Absorption barriers 
Ocular diseases are often treated with eye-drops or ointments. However the target 
tissues for most ophthalmic drugs are located in the inner eye and due to many 
biological barriers only a small fraction of the drug is absorbed in to the eye and reaches 
intraocular tissues. The main barrier for ocular absorption is the tightness of the corneal 
epithelium, but also lacrimal drainage and systemic absorption from the conjunctiva can 
wash away ocular drops. Basically drug absorption route from the surface of the eye can 
be either corneal or non-corneal. (Järvinen et al. 1995; Furrer et al. 2008) Due to the 
geometry and anatomy of the eyeball, drugs which are able to penetrate across cornea 
can reach the anterior segment of the eye such as cornea, aqueous humor and iris-ciliary 
body. In contrast, non-corneal absorption route across conjunctiva and sclera is more 
suitable for drugs which target tissues (choroid, retina, vitreous humor) locate in the 
posterior segment. (Ahmed 2003) 
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4.2.1. Corneal route of absorption 
Cornea is a thin avascular tissue that is composed of three main layers: epithelium, 
stroma and endothelium. The cross section of the cornea is presented in Figure 7. In 
order to penetrate the cornea, drug should first partition into very lipophilic epithelium, 
from which it must partition into hydrophilic stroma and finally into relatively lipophilic 
endothelium. Thus, drugs must have some solubility in both lipidic and aqueous 
environment. Most ocular drugs are transported across cornea by passive diffusion. 
Molecular size and weight, the degree of ionization and the permeation coefficient of 
the drug affect the rate of passive diffusion. Hydrophobic epithelium represents a 
limiting barrier for highly hydrophilic compounds while the hydrophilic stroma limits 
the penetration of highly lipophilic compounds. The much leakier corneal endothelium 
allows both para- and transcellular permeation of various drugs. (Furrer et al. 2008) 
 
Corneal epithelium is the main limiting barrier of drug absorption especially for 
hydrophilic drugs which must penetrate through paracellular route. Corneal epithelium 
has very tight intercellular junctions and epithelial pore size is estimated to be 2-3 
nanometers. (Hämäläinen et al. 1997a and b; Lee et al. 1986) Therefore only 
hydrophilic and very small drugs can penetrate corneal epithelium paracellular. The 
isoelectric point of cornea is 3.2 and at physiological pH corneal epithelia is negatively 
charged which makes the paracellular space more permeable to positive ions than to 
negative ions. (Rojanasakul & Robinson 1989). Most ocular drugs are however 
lipophilic enough to permeate transcellularly across cornea. Optimal lipophilicity for 
corneal permeation has been reported to be log P = 2–3. (Schoenwald & Ward 1978; 
Schoenwald & Huang 1983) 
4.2.2. Non-corneal route of absorption 
Non-corneal drug absorption into the intraocular tissues includes penetration across both 
conjunctiva and sclera. Conjunctiva is a thin, transparent, moist and relative leaky 
mucous membrane that coats the inner surface of the eyelids and the white part of the 
eyeball called sclera. Conjunctiva has large surface area, rich blood flow and it secretes 
a thick mucus gel that lubricates the eye. (Watsky et al. 1988, Hämäläinen et al. 1997b; 
Ahmed 2003) Conjunctiva is more permeable to drugs than cornea since it has leakier 
epithelium. (Prausnitz & Noonan 1998; Hämäläinen et al. 1997a and b) Conjunctiva has 
also four times larger surface area compared to cornea (Ahmed 2003). The pore size of 
the conjunctival epithelium has been estimated to be two times larger and the pore 
density 16 times higher than in the corneal epithelium (Hämäläinen et al. 1997a). 
Therefore the size and the lipophilicity of the drug do not limit conjunctival absorption 
as significantly as corneal absorption (Toropainen 2007).  
 
White sclera consists mainly of collagen and mucopolysaccharides (Keeley et al. 1984). 
It forms the supporting wall of the eyeball and is continuous with the transparent 
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cornea. Sclera maintains the shape of the eyeball by resisting intraocular pressure. It 
represents nearly 80 % of the surface area of the eyeball. (Battaglioli & Kamm 1984; 
Ahmed 2003) Sclera is generally more permeable tissue than conjunctiva and cornea 
(Toropainen 2007). Paracellular diffusion is assumed to be the main absorption 
mechanism across sclera. (Hämäläinen et al. 1997b) 
 
Non-corneal route across conjunctiva and sclera plays significant role for hydrophilic 
drugs and compounds with large molecular size which are poorly absorbed across the 
cornea (Ahmed & Patton 1985; Ahmed et al. 1987; Chien et al. 1990; Hämäläinen et al. 
1997a and b). The main problem of the non-corneal drug delivery is the risk of systemic 
absorption via conjunctival blood vessels and nasolacrimal system (Ahmed 2003). 
4.3. Drug formulation development to enhance ocular 
absorption 
Formulation development for ophthalmic drugs means designing a dosage form which 
provides a balance between absorption efficiency, formulation stability, sterility and 
ocular tolerance (see Figure 8). There are several ways to enhance ocular absorption and 
therapeutic efficacy of topically administered ophthalmic drugs. Generally these 
methods can be divided into two categories. Bioavailability can be enhanced either by 
increasing ocular penetration or contact time. 
 
 
 
Figure 8. Formulation parameters involved in topical ophthalmic drug development 
(Furrer et al. 2008). 
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Contact time can be prolonged for example by increasing the viscosity of the drug 
solution (Ding 1998; Kaur & Kanwar 2002). Ophthalmic gels, suspensions and 
ointments are however difficult to apply and their dosing is more inaccurate compared 
to eye drop solutions. Increased viscosity causes blurred vision which restricts the usage 
at day time. (Bapatla & Hecht 1996) Sticky sensation also induces lacrimation and 
reflex blinking which leads to faster elimination of the drug from the surface of the eye 
(Furrer et al. 2008; Dudinski 1983).  
 
New drug delivery systems are developed constantly. Contact time can be increased by 
using solid inserts which release drug at a constant rate for a certain time. These inserts 
can be either biodegradable, soluble or insoluble. The main problem of the inserts is that 
they give patients a sensation of a foreign body in the eye. Insoluble inserts also have to 
be removed after use. Drug release rate is however more accurate with insoluble inserts 
compared to soluble and biodegradable inserts which show larger variability between 
different patients due to different tear turnover rates and metabolic enzyme 
concentrations. (Furrer et al. 2008, Rathore & Nema 2009; Saettone & Salminen 1995; 
Del Amo & Urtti 2008) 
 
Drug delivery can be enhanced also by encapsulating drugs into transport vessels such 
as nanoparticles and liposomes (presented in Figure 9). Liposomes are structurally 
similar to phospholipid membranes and thus facilitate drug absorption across cell 
membranes by coming into close contact with membrane surface. (Furrer et al. 2008; 
Xu et al. 2013) The aqueous inner of the liposome can act as reservoir for hydrophilic 
drugs whereas surrounding lipid bilayer can uptake hydrophobic drugs (Xu et al. 2013). 
Figure 9. Schematic presentation of some transport vessels used in ocular drug 
delivery. Modified from ref. (Xu et al. 2013) 
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Nanoparticles are primarily polymer based delivery systems. Drugs can be either 
enclosed inside the nanoparticle (nanocapsule) or distributed throughout the polymeric 
matrix (nanosphere). Polymers with polar or ionized groups have electrostatic 
interaction with the negatively charged surface of cornea which increases the corneal 
contact time. Nanoparticles are more stable than liposomes and due to their small size 
they irritate ocular surface less. (Calvo et al. 1996; Monem et al. 2000; Smart 2005; 
Diebold et al. 2007; Xu et al. 2013)   
 
Preservatives are added to ophthalmic drug products primarily to inhibit microbial 
contamination, but as a side effect, they have been reported to promote ocular 
absorption (Freeman & Kahook 2009). Various penetration enhancers such as 
benzalkonium chloride (BAK), ethylenediaminetetraacetic acid (EDTA), non-ionic 
surfactants and bile salts have been investigated for their potential in improving ocular 
drug absorption. Amphiphilic surfactants can be easily diffused into the cell membrane. 
As the cell membrane gets saturated with these surfactants, they form micelles (see 
Figure 9) which affect membrane composition and solubilization. This process increases 
the transcellular transport of the active drug. Widely used preservative and cationic 
surfactant, BAK increases the solubility of hydrophobic drugs. BAK also has a high 
affinity for membrane proteins. It accumulates easily in corneal epithelium which 
benefits it as an absorption enhancer but can also lead to unwanted toxicity. Also bile 
salts can alter the integrity of the cell membrane and its lipid composition. This affects 
the rheological properties of the membrane and thus, enhances drug permeability. 
(Mitra 2013; Grass et al. 1985; Kaur & Smitha 2002; Marsh & Maurice 1971; 
Morimoto et al. 1987; Gasset et al. 1974) Chelators, such as EDTA, can increase 
paracellular drug absorption by loosening the tight epithelial junctions via calcium 
chelation (Tomita et al. 1996). 
 
Absorption rate can be affected by chancing the pH or the osmolality of the drug 
solution. Drug’s lipophilicity and solubility are highly dependent on the ionization stage 
of the drug which can be altered by adjusting formulation pH. Eye can tolerate slight 
moderation of pH.  However, adjusting pH below 6 or over 8 causes discomfort and 
enhances lacrimation which increases drug loss. (Furrer et al. 2008; Trolle-Lassen 1958) 
A large deviation from neutrality damages ocular tissues. Thus, pH values under 2 and 
over 11,5 are not acceptable in topical formulations. (Hurley et al. 1993) The natural 
osmolality of the tears is about 330 mOsm, but eye can tolerate slightly hypertonic and 
hypotonic solutions between 100 mOsm and 400 mOsm. Hypotonic solutions can be 
used to increase the absorption of the hydrophilic drugs due to solvent drag effect. 
(Chun et al. 2008) 
 
Drug absorption can be enhanced also by using high permeability prodrugs. Prodrugs 
are pharmacologically inactive derivatives of parent drug compounds which have 
increased permeability and/or solubility compared to the parent drugs. They can be 
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converted into active parent drugs after passing through the membranes. For example 
lipophilic esters can be used as prodrugs since they hydrolyse chemically to the parent 
alcohol and carboxylic acid. There are also prodrugs which can be converted into active 
drugs by enzymes such as esterases, ketone reductases or peptidases. (Furrer et al. 2008; 
Järvinen & Järvinen 1996; Lee & Bundgaard 1992; Tammara & Crider 1996) 
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5. MODELS FOR THE EVALUATION OF 
OCULAR DRUG PERMEATION 
5.1. Pharmacokinetic absorption studies in human 
The best model for the evaluation of drug absorption in man is no doubt a man (Davis & 
Wilding 2001).  Therefore absorption kinetics must be studied in human volunteers at 
some point of the drug development process (Dahiya et al. 2007). The rate and extent to 
which an active drug compound is absorbed from a drug product and becomes available at 
the site of drug action is called bioavailability. The bioavailability of systemic drugs is 
usually determined by measuring the concentration of an active substance in plasma as a 
function of time. (Chow 2014) Ocular pharmacokinetic studies in humans are 
unfortunately much more complicated since plasma level analysis does not usually 
correlate with the intraocular concentration and the ocular bioavailability of topically 
administrated drugs. However plasma level analysis might be useful if the systemic 
absorption of ophthalmic drug may cause some undesirable side effects. (Furrer et al. 
2008) 
 
Drug concentration in the aqueous and vitreous humor can be determined from patients 
undergoing surgical procedures such as cataract surgery (Koch et al. 2005) or 
vitrectomy (Puustjärvi et al. 2006). These methods are very invasive and hence ethically 
doubtful. Therefore, it is preferable to estimate the extent and rate of drug absorption 
from physiological responses. For example changes in intraocular pressure, miosis, 
mydriasis induced myopia or bactericidal activity can be easily measured and converted 
into bioavailability data. (Shell 1982; Furrer et al. 2008) Other non-invasive observation 
methods are gamma scintigraphy and fluorescent probes (Furrer et al. 2008). For 
example the corneal contact time of drugs in different formulations can be measured by 
gamma scintigraphy (Meseguer et al. 1996). Moreover pre-corneal contact time can be 
studied by measuring drug levels in tear (Walters et al. 2010). Tear sampling with 
pipette can however induce excessive blinking and tear production and therefore induce 
a bias in the results. Additionally, if drug formulation does not mix rapidly with the tear 
film, sampling even a small part of the formulation itself would lead to an 
overestimation. (Furrer et al. 2008) 
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5.2. Animal and tissue based models 
As described in previous chapter, the pharmacokinetic studies of ophthalmic drugs are 
typically invasive and therefore not suitable for in vivo human trials. Thus, animal 
testing is an essential part of the drug development before clinical human trials. 
Unfortunately studying ocular absorption with animals requires usually sacrificing them. 
After drug administration, eyes must be cut apart to measure drug concentrations in 
different sections of the eye. (Liu et al. 2010)  
 
Albino rabbit is the most commonly used animal model in ocular pharmacokinetic 
studies. Rabbits are relatively inexpensive and easy to handle. Rabbit’s eye has rather 
large ocular surface area. There is also important background literature on the ocular 
effects of the chemicals in rabbits. The rabbit eye and the human eye have quite similar 
cornea and aqueous humor composition. However, there are also some anatomical and 
physiological differences between human and rabbit eye. Rabbit has a third eyelid and 
no well-defined Bowman’s membrane. The blinking rate in rabbits is also much lower 
than in humans, which decreases precorneal drainage of topically applied drug 
solutions. (Plazonnet 2002) 
 
Ocular drug permeability can be estimated also ex vivo by preparing fresh excised 
animal tissues and placing them in an appropriate diffusion chamber. Franz diffusion 
cells and Ussing chambers are the most commonly used devices to study corneal 
absorption and penetration (Figure 10). These systems consist of a donor and a receptor 
chambers filled with physiological buffer solutions, separated by the studied tissue such 
as cornea or sclera. Drug solution is applied to the donor chamber and the amount of 
drug crossing the tissue is analyzed at relevant time points from the receptor chamber. 
Chambers are surrounded by water jackets to maintain constant biological temperature. 
The viability of the tissues can be prolonged by continuous gas flow of oxygen and 
carbon dioxide. Solutions can be stirred by magnetic stirrer or by gas lift. (Agarwal & 
Rupenthal 2016) 
Figure 10. Franz diffusion cell on the left and Ussing chamber on the right are the most 
commonly used devices to study drug permeability across tissues. (Agarwal & 
Rupenthal 2016, modified from ref. Todo et al. 2013 and Evitts 1990) 
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Rabbit, porcine and bovine corneas are the most commonly used tissues for ex vivo 
permeability modelling. Human corneas cannot be used for permeation studies since 
donated human corneas are reserved only for transplant purposes. Compared to the in 
vivo animal trials these tissue based permeation studies are more ethical. They are 
especially useful in early drug formulation development as long as inter-species 
variation is properly taken into account and diffusion cell assembly simulates 
physiological conditions. (Agarwal & Rupenthal 2016) 
5.3. Cell culture models  
For both ethical and economic reasons, there is pressure to develop and validate cheaper 
and ethically more acceptable new in vitro test methods in order to replace or reduce 
animal testing. It is actually required that animal experimentation should never be 
performed when an alternative experiment method exists (Council Directive 
86/609/EEC). Suitable in vitro cell culture models can reduce the need for animal 
testing. Typically these cell culture models are prepared by culturing harvested cells in 
appropriate growth medium and placed on a permeable filter. Drug permeability can be 
then measured by diffusion chambers described earlier in Chapter 5.2. (Agarwal & 
Rupenthal 2016) 
 
Generally there are three different types of cell culture models: primary cell cultures, 
immortalized cell lines and reconstructed whole cornea tissue cultures. Primary cell 
cultures are prepared by isolating the cells straight from the tissue of interest. Since 
corneal epithelium is the main limiting barrier of ocular drug absorption, corneal 
epithelial cells are most commonly studied. Cell cultures can be prepared either from 
animal or human corneal epithelial (HCE) cell tissues, but due to the slower cell 
proliferation rate and the finite availability of human tissue, rabbit and rat tissues are 
more commonly used. Primary cell cultures typically consist of 5-6 cell layers. They are 
relatively cheap and easy to prepare, but the cultivation process is time-consuming and 
primary cell cultures have limited lifespan, because normal cells do not divide infinitely 
but die over time. (Agarwal & Rupenthal 2016; Toropainen 2007) 
 
Immortalized cell lines however are capable of infinite cell proliferation due to the 
mutations. These cell lines can be obtained from tumors or modified from normal 
primary cells by chemicals or viral vectors that activate the mechanism for maintaining 
telomere length. The main advantage of immortalized cell lines is that the same cell line 
can be utilized over and over again which guarantees a level of continuity that primary 
cells cannot provide. However, the longer these cell lines are cultured the more likely 
they develop new mutations and chromosomal abnormalities which can alter for 
example enzyme expression and growth characteristics of cells. (Agarwal & Rupenthal 
2016; Toropainen 2007)  Both primary cell cultures and immortalized cell lines have 
shown promising results in permeation studies (Agarwal & Rupenthal 2016). Especially 
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HCE-T cell line simulates well human cornea and C-HCE cell line has shown good 
correlation with excised rabbit corneas (Toropainen et al. 2001; Xiang et al. 2009).  
 
The main limitation for both primary and immortalized cell culture models is that the 
epithelial cell lines do not represent the whole cornea but only the epithelium. 
Reconstructed whole cornea tissue cultures however contain all three cell types of the 
cornea. Epithelial, stromal and endothelial cells are cultivated above each other. Three-
layered construction mimics the morphology and the physiology of human cornea more 
accurately than epithelial layer alone. (Agarwal & Rupenthal 2016; Toropainen 2007) It 
has been reported to be very applicable model for corneal irritation and toxicity 
estimation (Griffith et al. 1999). The whole corneal construct models have been used in 
permeability studies as well. Drug permeation across whole corneal construct model has 
been reported to be faster than trough excised corneas, but model show the same 
permeation rank order for the different drug formulations, which indicates that the 
barrier functions of the whole cornea tissue culture and the excised cornea are quite 
similar (Tegtmeyer et al. 2001). Unfortunately these three-dimensional cornea 
constructs have not been extensively studied. Therefore there is no evidence that these 
more complex models are more beneficial compared to simpler epithelial models. 
(Rönkkö et al. 2016) 
 
One of the greatest challenge for cell culture models in the lack of standardization. 
Interlaboratory data comparison is difficult due to the differences in experimental 
conditions, cell sources and cell culturing methods. The use of reference compounds in 
permeation studies and transepithelial electrical resistance (TER) measurements of the 
cell cultures support standardization between laboratories. (Mälkiä et al. 2004) 
5.4. Artificial membranes and PAMPA 
Permeability measurements that utilize artificial lipid membranes can be classified in-
between biological and physicochemical methods. PAMPA (parallel artificial 
membrane permeability assay) is a widely used high-throughput technique developed 
for the evaluation of the passive transcellular permeability of drugs. It was first 
introduced by Kansy et al. 1998.  In this system an artificial membrane immobilized on 
a 96-well filter plate is placed between a donor and acceptor compartments (Figure 11).  
In the beginning of the test, buffer solution containing the analytes is introduced in the 
donor compartment and a fresh buffer solution is placed in the acceptor compartment. 
Two compartments are then assembled into a “sandwich-like” configuration and 
incubated for a determined time, after which the analyte concentrations in both the 
donor and acceptor compartments are measured and compared with initial concentration 
in the donor compartment. Concentrations can be measured by UV spectrophotometry 
using a 96-well microplate photometer. (Kansy et al. 1998; Kerns & Di 2004) 
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Figure 11. Parallel artificial membrane permeability assay. (Pion-inc 2018) 
 
Artificial membrane can be formed by impregnating the supporting filter plate with 
organic solution containing phospholipids. Therefore this membrane is totally artificial 
and does not contain any inter-cellular pores or active transport system. (Kansy et al. 
1998) Depending on the lipid composition of the artificial membrane, different barrier 
tissues can be simulated. Because most drugs are administered orally, intestinal 
absorption has been studied most extensively. In the original PAMPA method, artificial 
membrane was created by immersing a lipophilic microfilter in phosphatidylcholine 
(egg lecithin) dissolved in n-dodecane, as mammalian membranes are predominantly 
composed of phosphatidylcholine (Kansy et al. 1998). Cholesterol has often been added 
to previous mixture due to its significance in natural mammalian membranes (Sugano et 
al. 2001). It has been also demonstrated that some solvents alone, such as n-hexadecane 
can model the membrane permeability sufficiently (Wohnsland & Faller 2001).  
 
PAMPA models have been developed also to mimic blood-brain barrier (BBB) and skin 
permeability. Artificial membrane containing porcine brain tissue extract dissolved in 
dodecane is able to model accurately compounds which pass the BBB and those which 
poorly penetrate the BBB. (Di et al. 2003) Membrane consisting of isopropyl myristate 
and silicone oil is able to mimic the human stratum corneum and can be used to predict 
passive human skin permeability (Ottaviani et al. 2006). Artificial membrane containing 
corneal epithelium membrane lipid mixtures is surely possible to develop, but so far 
PAMPA models have not been studied specifically for ocular permeation. Therefore, 
true benefits of PAMPA in comparison with cell culture models are still open in 
ophthalmic drug development. PAMPA however is a high-throughput technique that 
allows rapid determination of permeability profiles for different formulations over wide 
pH range, which is more difficult to obtain from cell culture experiments (Wohnsland & 
Faller 2001). 
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6. PREDICTING DRUG PERMEATION BY 
PHYSICOCHEMICAL PARAMETERS 
As has been demonstrated earlier in Chapter 3, physicochemical properties such as the 
molecular size, ionization constants, lipophilicity, solubility and hydrogen bonding 
property of pharmaceutical products have a huge impact on membrane permeability and 
bioavailability. Thus, these properties can be used to predict drug absorption. 
Physicochemical analysis methods are attractive because they predict passive drug 
permeation reproducibly and efficiently. These methods also have great high throughput 
potential and they require less resources and manpower compared with many other in 
vitro permeability prediction methods. However, these methods do not take into account 
physiological conditions or any specific interactions between drugs and membrane. 
(Balimane et al. 2000) 
 
6.1. Experimental determination of ionization constant 
The ionization constant pKa of the drugs are traditionally measured by potentiometric 
method, but also UV spectrophotometry, capillary electrophoresis and liquid 
chromatography can be used. The determination of pKa by reversed phase high 
performance liquid chromatography is introduced more detailed in chapter 7.3.  
 
6.1.1. Potentiometric titration 
In potentiometric titration a precisely known volume of standardized strong acid or base 
solution is added to a stirred solution of an ionizable analyte compound and the pH of 
the solution is continuously measured with a standardized electrode which has been 
calibrated beforehand by blank titration. The pKa is determined from the titration curve 
(Figure 12) at the point where the half of the compound is in the ionized form and half 
is in the unionized form. At this point pH is equal to pKa. (Avdeef & Testa 2002) 
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Figure 12. Titration curve of weak acid with strong base. pKa can be determined from 
the titration curve at the point where half of the compound is in the ionized form and 
half is in the unionized form. At this point pH is equal to pKa. (Asdlib2018) 
 
Since pKa depends on both temperature and ionic constant, ionic strength should be 
adjusted to physiologically relevant 0,15 M by using NaCl or KCl and the temperature 
must be kept constant at 25 °C. If the aqueous solubility of the analyte compound is 
insufficient, potentiometric titrations are performed at different co-solvent 
concentrations and the aqueous pKa value is deduced by extrapolating the pKa value to 
zero co-solvent concentration. Titrations can be performed manually, but also 
automated high-throughput commercial instruments has been developed (e.g. the Sirius 
GLpKa from Sirius Analytical Instruments). This automated technique takes 30-60 
minutes per titration and requires a milligram amount of analyte. (Avdeef & Testa 2002, 
Kerns 2001) 
6.1.2. Spectrophotometric pKa determination 
Spectrophotometric pKa determination is based on the change in absorption of 
chromophores that are close to the ionization centers of the compounds. Ionization 
constants can be determined from a plot of absorbance as a function of pH. (Henchoz et 
al. 2009) Multiwavelength spectrophotometric titration method combines diode array 
detector, automated pH titrator and elaborate data treatment. With this method even 
multiprotic compound with overlapping pKa values can be characterized. (Allen et al. 
1998) For a high through-put demand a spectral gradient analysis (SGA) method has 
been developed and commercialized. In SGA technique, samples are delivered to the 
instrument in 96-well plates, after which solutions are automatically diluted and injected 
into a mobile phase that passes through a diode array UV detector. Mobile phase 
composition is altered continuously by mixing varying amount acidic and basic buffers 
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to create linear pH gradient over a period of 2 minutes. The determination of pKa values 
of a compound takes only 4 minutes. Thus, the trough-put of this instrument is over 240 
compounds per day. Since spectrophotometric determination is usually more sensitive 
than potentiometric method, sample consumption is lesser. However, this technique can 
be utilized only for compounds having a measurable pH dependent UV chromophore. 
(Kerns 2001; Box et al. 2000 and 2003]  
6.1.3. Capillary zone electrophoresis 
Ionization constants can be determined also by capillary zone electrophoresis (CZE). 
CZE is a chromatographic separation technique in which analytes are dissolved in 
buffer solution and separated in narrow fused-silica capillaries under the applied 
electrical field (Figure 13). The ends of the capillary are immersed into reservoirs filled 
with background electrolyte (BGE) solutions, which also contains electrodes. The 
migration of the analytes is initiated and maintained by a constant electric field created 
by high voltage supply. Due to the electro osmotic flow (EOF) all ions are pulled 
through the capillary in same direction. The analytes separate as they migrate due to 
their electrophoretic mobility. (Skoog et al. 2007; Piaggio & Deiber 2003) 
 
 
 
Figure 13. Schematic presentation of the capillary electrophoresis system. (Piaggio & 
Deiber 2003) 
 
To determine the pKa value of a compound, the effective mobility μeff of the compound 
is measured using mobile phases buffered at different pH values. The ratio between 
ionized and unionized depends on the pH. Because electrophoretic mobility is 
proportional to charge, the mobility of the compound is also pH dependent. (Kerns 
2001) Effective mobility at different pH values can be calculated as: 
 
𝜇௘௙௙ = ௅೐೑೑∙௅೟೚೟௎ ∙ ቀ
ଵ
௧ೌ −
ଵ
௧ಶೀಷቁ        (9) 
 
where ta and tEOF are the migration times of the analyte and the neutral marker 
compound that are carried through the capillary by the EOF, U is the applied voltage, 
Ltot is the total capillary length and Leff is the effective capillary length. The pH 
depended variation of EOF can be corrected by using a neutral marker. The pKa values 
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are obtained by fitting μeff as a function of pH to a suitable model for the number of 
ionizable groups. (Henchoz et al. 2009; Poole et al. 2004) 
 
Although CZE has not been used as widely as potentiometric or spectrophotometric 
techniques to determine pKa values, it has several advances compared to them. Sample 
consumption is very low (1-50 nl sample at concentrations of 10-500 μM), 
instrumentation is highly automated, impure samples can be measured, knowing the 
sample concentration is unnecessary since only mobilities are used in calculations and 
resolving power is excellent. (Henchoz et al. 2009; Poole et al. 2004) Multiprotic 
compounds having even seven ionization groups have been successfully characterized 
(Ishihama et al. 1994). This technique is also universal, because CZE can be combined 
with several different detection systems. The photodiode array is however the most 
commonly used detector for routine pKa measurements. (Poole et al. 2004)  
 
There are however also some drawbacks considering CZE. Major challenges with CZE 
method are the need of multiple experiment points at different pH values and the long 
migration times at low pH due to the limited EOF. To increase the throughput, dynamic 
coatings can be used create a high EOF. Migration times can be decreased also by using 
high external pressure or vacuum. For this purpose, pressure-assistant capillary 
electrophoresis (PACE) and vacuum-assisted 96-channel capillary electrophoresis has 
been developed. Choice of the buffer, applied voltage and the detection technique must 
be considered carefully to obtain reliable pKa values by CZE (Henchoz et al. 2009). 
6.2. Determination of lipophilicity by octanol-water 
partition coefficient 
 
As has been told earlier in Chapter 3.3 the octanol-water partition coefficient (Pow) is 
the most widely used measure of the lipophilicity of drugs (Mälkiä et al. 2004). There 
are however numerous different methods to measure and estimate Pow. Octanol-water 
partition coefficient can be directly measured by traditional shake-flask method or by 
slow stirring method. It can be also estimated by theoretical calculations or by indirect 
experimental methods such as potentiometric titration or reversed phase high 
performance liquid chromatography (RP-HPLC). (Kah & Brown 2008) 
Chromatographic methods will be described separately later in Chapter 7.4 while the 
other methods are presented forthwith.  
 
Octanol-water partition coefficient is traditionally measured by shake-flask method. 
This method is appropriate for non-ionized compounds having log Pow in range of -2-4. 
Briefly, an analyte compound is dissolved in either n-octanol or water depending on its 
solubility, the remaining solvent is added to previous solution and the analyte-octanol-
water mixture is shaken or stirred until equilibrium is reached. The organic and aqueous 
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phases are then separated, usually by centrifugation, and the concentration of the analyte 
compound in both phases is measured. (OECD 1995) Pow can be then calculated from 
following equation: 
 
o
w
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o
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cP ×=          (10) 
 
where co and cw are the analyte concentrations in octanol and water phases and Vo and 
Vw are the solvent volumes respectively (Gynther et al. 2003). Concentration 
determinations are usually performed by spectrophotometry, gas chromatography or 
high performance liquid chromatography. It must be calculated beforehand that the final 
concentration of analyte in each phase will be high enough to be analyzed by chosen 
analysis method, but still be less than 0,01 M. (OECD 1995) Basically this procedure is 
very simple, but in reality it is messy, time-consuming and requires relatively large 
amounts of solute (Mälkiä et al. 2004). Before a partition coefficient can be determined, 
octanol and water phases must be mutually saturated at the temperature of the 
experiment. Saturation can be achieved by shaking two large stock bottles, one 
containing n-octanol and a sufficient quantity of distilled water, and the other containing 
distilled water and a sufficient quantity of n-octanol, for 24 hours, after which bottles 
are let to stand long enough to allow the phases to separate. Accurate and reliable 
partition coefficients can be obtained by making duplicate determinations under three 
different test conditions by varying the solvent volumes. The determined log Pow values 
should fall within a range of ± 0,3 log units. Due to the formation of octanol emulsions 
in water, substances with high lipophilicity (log Pow > 5) cannot be determined by this 
method. (OECD 1995 and 2004) 
 
Slow-stirring method follows the same principle as shake-flask method. However, in 
this method the two phases are equilibrated under very slow stirring to avoid emulsion 
formation. Typical phase ratios used are 20-50 ml of n-octanol and 950-980 ml of water, 
total volume being a liter. Log Pow values up to 8.2 have been accurately determined 
(De Bruijn et al. 1989). Therefore, slow-stirring method is suitable for highly lipophilic 
compounds that cannot be measured by shake-flask method. The whole procedure is 
however time consuming. Sampling of compound with log Pow estimate less than five 
takes two to three days, but for a compound with log Pow 8.23 even 144 hours 
equilibrium time was necessary. (OECD Proposal) 
 
For ionizable compounds log Pow values can be determined by potentiometric titration. 
This technique is similar to the potentiometric pKa measurement described earlier in 
Chapter 6.1.1. Pow determination however consists of two linked potentiometric 
titrations. Typically, a pre-acidified solution of weak acid is titrated first with 
standardized base to some appropriately high pH to measure pKa value in water phase. 
Octanol is then added and the mixture is titrated back to the starting pH to measure the 
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apparent pKa value (poKa) of test compound in two-phase system. If the test compound 
partitions into the octanol phase, pKa values derived from the aqueous and the dual-
phase titration curves are different. A large difference between pKa and poKa indicates a 
large value of log Pow. Depending on the nature of ionizable analyte compound, 
different equations can be used to derive Pow from pKa and poKa values. For example, 
the log Pow value for neutral species of monoprotic compound can be calculated using 
the following equation: 
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where r is the volume ration Vn-octanol/Vwater. Before any measurements it is useful to 
have an estimate of Pow value to choose optimum volume ratio r used in titrations. The 
basic principle is that the lower the estimated log Pow values the larger the values of r 
are required for measurement. In order to obtain reliable Pow values, at least three 
determinations should be made. The determined log Pow values should fall within a 
range of ± 0,1 log units. The main advantage of this method is that it provides a pH 
profile of partitioning. Determination of log Pow for ionizable and multiprotic 
compounds is appropriate in the range -2 to 7. (OECD 2000) Titrations can be 
performed manually, but the entire operation of titrations and calculations has also been 
automated. Previously described high-throughput commercial instrument (Sirius GLpKa 
from Sirius Analytical Instruments) can be used to determine both pKa, poKa and log Pow 
values.  
 
Filter probe method is similar to the potentiometric method except that the partitioning 
is determined by spectroscopy instead of potentiometry.  An aqueous solution of analyte 
is placed in a reaction vessel and circulated through an UV flow cell. The absorbance of 
the aqueous solution is measured both before and after addition of octanol. If the analyte 
partitions into the octanol phase, the absorbance of the aqueous solution is decreased. 
To prevent any octanol from passing through to the detector a solvent inlet filter is used. 
Log D profiles can be obtained by performing the experiments at different pH values.  
The method is rapid and reliable but cannot be applied for molecules having log P 
values less than 0.2. It is also required that the analyte compound has an isobestic point 
in its UV spectrum. Isobestic point is a specific wavelength at which the absorption 
spectra of both ionized and neutral species cross each other. (Kah & Brown 2008; Niazi 
2007) 
 
Although octanol-water partition coefficient is the most extensively used measure of the 
lipophilicity of drugs, it has been criticized for supporting hydrogen bonding which can 
lead to permeability overestimation for drugs which are capable of forming hydrogen 
bonds (Mälkiä et al. 2004). The hydroxyl group of n-octanol can act both as a hydrogen 
donor and an acceptor. However, different types of cell membranes have distinct 
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hydrogen bonding properties. Thus, alternative solvents such as chloroform, dibutyl 
ether, cyclohexane, dodecane and 1,2-dicloroethane have been proposed to imitate 
different kind of membranes. Octanol is the most suitable solvent when target 
membranes contain amphiprotic groups, whereas chloroforms suits well for the 
membranes containing mainly hydrogen donors and dibutyl ether for the membranes 
containing mainly hydrogen acceptors. If the target membrane contains neither 
hydrogen donors nor acceptors, alkanes such as cyclohexane and dodecane can imitate 
the membrane barrier. (Hartmann & Schmitt 2004; Giaginis & Tsantili-Kakoulidou 
2008) Since many compounds have low alkane solubility, 1,2-dicloroethane has been 
proposed to replace alkanes in partitioning experiments (Steyaert et al. 1997).  
 
In addition, liposome-water systems have been used to model drug partition into 
biological membranes. Especially, for charged compounds octanol-water system often 
fails to model electrostatic interactions between the drug and the membrane (Esteves et 
al. 2013). Liposomes that are converted from phospholipids, usually from 
phosphatidylcholines, can simulate the electrostatics of the lipid bilayer more 
authentically (van Balen et al. 2004). Despite the weaknesses of octanol-water system 
and the increasing popularity of liposomal partitioning determination, n-octanol has 
remained as the main solvent for partition experiments.  Due to the huge log Pow 
databases it can be considered as the reference system for lipophilicity estimation 
(Giaginis & Tsantili-Kakoulidou 2008). 
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7. LIQUID CHROMATOGRAPHY METHODS IN 
DRUG PERMEATION STUDIES 
7.1. High performance liquid chromatography as a 
separation method 
Chromatography is a separation method, in which components to be separated are 
distributed between two immiscible phases, stationary and mobile phase. Components 
of the mixture are separated as they travel in mobile phase that flows through the 
stationary phase. Separation is based on differences in migration rates along sample 
components. It occurs due to the different interaction of each sample component with 
the stationary and mobile phases. The stationary phase can be either solid or liquid, 
while the mobile phase is usually either liquid or gas. The techniques are named after 
the mobile phase as gas chromatography (GC) or liquid chromatography (LC). 
 
High performance liquid chromatography (HPLC) is a form of liquid chromatography 
in which analytes are dissolved in liquid mobile phase called eluent vie sample injector, 
and the solution is forced to pass through a chromatography column containing 
stationary phase under high pressure at certain flow rate. Many systems also include an 
oven for the temperature control of the column. Compounds are separated, since they 
travel at different individual speeds through the column. Separation efficiency depends 
both on the choices of mobile and stationary phases. Separation is monitored with flow-
rate detector and chromatographic data is presented as a graph of detector response 
against elution time, which is called chromatogram. Examples of chromatograms are 
presented in Appendix 1. As a result, HPLC has the ability separate, identity and 
quantitate a wide variety of chemicals and their mixtures. (Harris 2007; Kazakevich & 
LoBrutto 2007) 
 
From the chromatogram several important parameter can be deduced to characterize the 
efficiency of separation and column efficiency. The most important parameter in the 
chromatographic measurement is the time taken for a particular compound to travel 
through the column to the detector, called retention time, tr. This time is measured 
between the injection point and the maximum detector response of correspondent 
compound. The retention times can be directly measured from the chromatogram. 
Retention times are highly dependent on the geometry of the column, nature of the 
stationary and mobile phases, temperature and flow rate. [Harris 2007; Kazakevich & 
LoBrutto 2007) 
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The more universal retention parameter is a retention (capacity) factor k, defined as: 
 
𝑘 = ௧ೝି௧బ௧బ           (12) 
 
where to is the retention time of an unretained component and tr is the retention time of 
the analyte respectively. Retention factor is independent on mobile phase flow rate and 
geometry of the column. Ideally, if the retention of the same sample is measured with 
same stationary and mobile phase by different instruments, theoretically the retention 
factors should be identical. This allows comparison of the results between different 
instruments and laboratories. [Harris 2007; Kazakevich & LoBrutto 2007) 
7.2. Classification of separation methods in HPLC 
 
Liquid chromatographic methods can be classified depending on the interaction 
mechanism between solute and stationary phase. In adsorption chromatography 
stationary phase is an absorbent and the separation is based on repeated absorption-
desorption steps. The solute competes with the solvent for binding sites. The stronger 
the solute is absorbed the slower it passes through the column. In partition 
chromatography both stationary and mobile phases are liquids and the separation is 
based on the selective partition of solute between them. Ion-exchange chromatography 
utilizes the differences in ion-exchange properties of solutes, and the exclusion 
chromatography separates molecules by size. The most selective kind of 
chromatography, affinity chromatography is based on a specific interaction between an 
analyte molecule and a second molecule, for example an antibody immobilized on 
stationary phase. (Harris 2007) 
 
Adsorption chromatography can be further divided into two different categories, 
normal-phase (NP) and reversed-phase (RP) chromatography. In normal-phase 
chromatography polar stationary phases, such as silica gel, and non-polar mobile phases 
are used. Hydrophilic solutes are retained stronger on the surface of the stationary phase 
than hydrophobic solutes. As opposite to NP-HPLC, in reversed-phase chromatography 
the polarities of mobile and stationary phases are reversed. The surface of the stationary 
phase is non-polar and mobile phase is polar. RP-HPLC is the most commonly used 
form of chromatography. (Harris 2007; Kazakevich & LoBrutto 2007) 
 
Liquid chromatographic methods can be classified also by elution types. There are two 
different elution types: isocratic and gradient elution. In isocratic elution the eluent 
composition is kept constant during the whole analysis. In gradient elution, the eluent 
composition is steadily changed during the run. (Harris 2007) 
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7.3. HPLC method to determine pKa 
RP-HPLC can be used to determine the ionization constant of ionizable drugs. Method 
was first reported by Horvath et al (1977). The chromatographic retention of ionizable 
compound is highly dependent on the pKa of the analyte and the pH of the mobile phase. 
The neutral forms of the compounds are well retained due to their high affinity to the 
lipophilic stationary phase. Ionized forms have shorter retention times because they are 
more soluble in polar mobile phase respectively. When the pH of the mobile phase is 
lower than the pKa of a weak acid, the compound will be in neutral form. Thus weak 
acids will retain more at low pH than at high pH. Conversely weak basics are in neutral 
form and well retained when the pH is higher than the pKa. (Horvath et al. 1977; 
Wiczling et al. 2004; Gynther et al. 2003) 
 
Since the pH of the mobile phase affects the retention of ionizable compounds, pKa of 
the compound can be determined by measuring the retention times of the drug 
compound at 8-10 different pH of the eluent and plotting the retention factor k as a 
function of pH. For weak acids the dependence of k and pH can be illustrated by 
following equation: 
 
𝑘 = ௞ಹಲା௞ಲష×ଵ଴೛ಹష೛಼ೌଵାଵ଴೛ಹష೛಼ೌ         (13) 
 
where kHA and kA- refer to the retention factors of the deprotonated and the protonated 
forms of acid respectively. At the point where pH equals to the pKa value of the 
compound, Equation 13 can be simplified in form: 
 
𝑘 = ௞ಹಲା௞ಲషଶ           (14) 
 
Thus, pKa value can be determined from the graph at the point where retention factor k 
is the average of the retention factors of unionized and ionized forms. Ideally, these 
isocratic measurements should be made in aqueous buffer solutions, but the retention 
times for neutral forms are typically so long in aqueous mobile phase that some organic 
solvent must be added to the mobile phase to speed up the elution. Unfortunately, the 
addition of organic solvent affects both the pH of the eluent and the ionization of weak 
acids and bases which complicates the estimation of pKa values. Thus, pKa values 
obtained by RP-HPLC are typically rough estimates. (Kazakevich & LoBrutto 2007; 
Horvath et al. 1977; Valkó 2016; Hardcastle & Jano 1998; Wiczling et al. 2004; 
Kaliszan et al. 2002)  
7.4. HPLC methods to determine lipophilicity 
Retention of a compound in RP-HPLC is mostly governed by its lipophilicity, since the 
retention time relates to the compound’s distribution between the polar mobile phase 
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and nonpolar stationary phase. Retention factor k is equal to the ratio of the amounts of 
a sample component in the stationary and mobile phases respectively. Therefore directly 
measured retention factors are lipophilicity indices on their own. However retention 
factors can be also converted to log Pow scale by using standards and correlation 
equations. (Avdeef & Testa 2002; IUPAC Gold Book) 
 
Lipophilicity measurements can be performed in either isocratic or in gradient mode. 
Isocratic log k values are a relative scale of lipophilicity on their own.  However log k 
values are usually extrapolated to pure water log kw values to obtain more comparable 
lipophilicity indices. In order to do this, log k values are determined at various 
concentrations of organic solvent in mobile phase. There is a linear relationship between 
the volume fractions of organic solvent in mobile phase ϕ  and the logarithmic retention 
factor log k: 
 
wkSk loglog +−= ϕ         (15) 
 
where S is the slope. Linearity holds optimally for organic solvent concentrations within 
the rage -0.5 < log k < 1.5.   (Pallicer et al. 2010; Valkó 2012) Extrapolated pure water 
log kw values can be also converted into more comparable octanol-water partition 
coefficients. The correlation requires calibrating the HPLC-system with at least six 
reference compounds for which both measured log kw values and log Pow values are 
known. If possible, reference substances should be structurally related to the test 
substance and at least one of the reference substances should have a log Pow above and 
another a log Pow below that of the test substance in order to avoid the need of 
extrapolation. (OECD 2004) 
 
Another lipophilicity parameter, chromatographic hydrophobicity index (CHI) ϕ 0  can 
be obtained at the point where the line wkSk loglog +−= ϕ  intersect with the x-axis by 
the following expression:  
 
S
kwlog
0 =ϕ          (16) 
 
This parameter, ϕ 0 , is equal to the organic modifier fraction in the mobile phase at 
which the log k = 0. ϕ 0 varies from 0 to 100 for the most compounds. CHI values have 
shown relatively good correlation to log Pow values even for structurally unrelated 
compound (Valkó et al. 1993, 1997 and 2012) 
 
The main disadvantage of the isocratic CHI method is the need of several retention time 
measurements for the same compound which consumes time and resources. Therefore, 
fast gradient method has been developed to determine the CHI values. In this method 
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the gradient retention times of the reference and the analyte compounds are measured 
by applying the linear increase of the organic solvent fraction from 0 to 100 %. Due to 
high flow rates and short column lengths analyses are usually performed in less than 5 
minutes. Acetonitrile is most commonly used as an organic solvent. Gradient retention 
times show good correlation with isocratic CHI ϕ 0 values because it can be assumed 
that the injected samples are absorbed to the stationary phase of the column and are not 
desorbed until the mobile phase composition reaches a certain sample specific organic 
phase concentration after which the compounds elute rapidly through the column. Thus, 
by a performing a simple linear regression, the measured gradient retention times tr can 
be converted into the CHI values of the test and reference compounds after defining the 
coefficients A and B of following equation: 
 
CHI = Atr + B         (17) 
 
The CHI values of the reference compounds can be obtained from literature. For 
example GlaxoSmithKline has measured the CHI values for more than half a million 
compounds. (Valkó et al. 1997, 2012 and 2016) 
7.5. Biomimetic chromatography  
HPLC technique can be utilized to study also more specific biomimetic properties of the 
drugs such as phospholipophilicity and protein binding. In these applications stationary 
phases have been designed to imitate the biological environment. (Valkó 2016) Several 
methods have been developed to mimic the partitioning of the drugs into the 
phospholipid bilayers. Commercialized immobilized artificial membrane (IAM) 
chromatography utilizes stationary phases in which phosphatidylcholine lipids are 
covalently attached on silica resins to form ordered phospholipid surfaces (Pidgeon et 
al. 1995). Immobilized liposome chromatography (ILC) has similar idea, but in this 
technique lipids are bound to silica gel beads to form multi- or unilamellar vesicles (Liu 
et al. 2002). Biopartitioning micellar chromatography (BMC) uses common RP-HPLC 
stationary phases and surfactant is added to mobile phases to produce biomimetic 
micelles (Molero-Monfort et al. 2001; Escuder-Gilabert et al. 2004). The advantage of 
these methods is the ability to imitate the structure of biological membranes and 
therefore the results correlate generally well with biological permeation. (Valkó 2016) 
 
Protein binding can heavily affect the bioavailability of the drugs, because proteins can 
act as reservoirs of the drugs. Drug’s potential is therefore dependent on its affinity bind 
in proteins. (Trainor 2007; Schmidt et al. 2010) Drug-protein binding for at least two 
different plasma proteins has been characterized by HPLC. In these methods human 
serum albumin (HSA) or alpha-1-acid glycoprotein (AGP) have been immobilized on 
stationary phase by bonding them chemically to silica particles. Aqueous buffers have 
been typically used as mobile phase, but if studied compounds bind very strongly to the 
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protein stationary phase, 2-propanol can be used to increase eluent strength. However, 
high organic phase concentrations can denature protein stationary phases. Measured 
retention factors can be converted into percentage protein binding. (Valkó 2016; 
Vuignier et al. 2013) 
7.6. Ion-pair chromatography 
Ion-pair chromatography (IPC), also called as ion-interaction or solvent generated ion-
exchange chromatography is a mode of HPLC method between ion-exchange and 
reversed phase chromatography. It can be performed on standard reversed phase 
columns, such as C18-columns, using ion-pair reagents in hydro-organic mobile phases. 
Ion pair reagents are usually amphiphilic molecules having a hydrophobic hydrocarbon 
chain and a charged head group. Addition of these ionic additives in mobile phase 
affects retention behavior of ionic or ionizable analytes. (García-Álvarez-Coque et al. 
2017; Kazakevich & LoBrutto 2007) Thus, ion-pair chromatography could be utilized 
for example in revealing ion-pair formation between drugs and formulation excipients. 
 
There are numerous competing theories for describing the retention mechanisms of IPC. 
In principle ion-pair formation can occur either in mobile phase or at the surface of 
stationary phase. Non-polar end of the amphiphilic counter-ion can be adsorbed on the 
hydrophobic stationary phase surface leaving the charged head group sticking out to the 
mobile phase. This creates a charged surface which attracts oppositely charged analyte 
molecules and increases their retention. On the other hand ion-pairing between ion-pair 
reagent and analyte can take place also in mobile phase after which this neutral complex 
is retained more strongly due to preferable partition into the stationary phase. In reality 
probably both mechanisms coexist. (Kazakevich & LoBrutto 2007; Moldoveanu & 
David 2013; García-Álvarez-Coque et al. 2017) 
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8. INTRODUCTION TO EXPERIMENTAL STUDY 
Experimental part of the thesis was performed in the Quality Control and Analytical 
Development Laboratory of Santen Oy during September 2010 – January 2011. 
Physicochemical laboratory models have not been widely utilized for developing 
ophthalmic formulations in Santen Oy. Pre-clinical pharmacokinetic studies have been 
primarily based on in vivo studies in animal models. Furthermore formulation 
development had mainly relied on physicochemical parameters obtained from literature 
or supplied by ingredient manufactures. However, availability of this information is 
quite poor and parameters are often rough estimates. Thus, developing in-house 
physicochemical laboratory models to determine formulation parameters would improve 
the formulation development. Ideally simple laboratory models could explain or even 
predict the pharmacokinetic studies performed in animals. 
 
The main idea for experimental study was to find out if common RP-HPLC instruments 
could be exploited in ophthalmic drug formulation development. As was demonstrated 
in theoretical part of this thesis, lipophilicity of a drug compounds can be estimated 
from its retention behavior in RP-HPLC. In this study, lipophilicity of five ophthalmic 
drug compounds was studied by common C18-HPLC system. For each compound, 
lipophilicity expressed as log k, was measured over a wide pH range to obtain pH-
lipophilicity profiles which could be utilized while choosing the optimal formulation 
pH. It was also studied if some specific formulation additives affect the lipophilicity of 
these drug compounds. 
 
Experimental part is divided into three different chapters. In the first chapter, 
lipophilicity of two commercial isopropyl ester prodrugs (1e and 2e) and their 
biologically active metabolites (1a and 2a) are studied by HPLC. Chapter consists of 
eluent optimization for further lipophilicity measurements and retention behavior 
studies over a wide eluent pH range. Moreover, it is studied if some specific interactions 
such as ion pairing, between these drug molecules and additive X could be revealed 
with a C18-HPLC-system by adding increasing amount of the additive X into the 
eluent. 
 
In the second chapter, a modified shake-flask method is set up for determining direct 
log Pow values of drugs at Santen Oy.  Lipophilicity (log Pow) of prodrug 2e with and 
without additive X is directly measured by this method in order to compare results 
obtained in previous chapter by RP-HPLC method. 
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In the third chapter, usefulness of the C18-HPLC method for studying drug-additive 
interactions is put to the test. Method is validated by using common anti-glaucoma drug 
timolol and a sorbate additive, for which ion pairing had been previously verified by 
NMR (Higashiyama et al. 2007). Before ion pairing studies, the eluent composition is 
optimized for timolol. Additionally, the pH-lipophilicity profile of timolol is measured. 
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9. HPLC STUDIES OF ISOPROPYL ESTER 
PRODRUGS AND THEIR ACID FORMS 
9.1. Background and purpose of the study 
In this chapter, lipophilicity of two commercial isopropyl ester prodrugs (1e and 2e) and 
their biologically active metabolites (1a and 2a) are studied by HPLC. Chapter begins 
with eluent optimization and lipophilicity measurements, after which retention behavior 
is studied over a wide eluent pH range. Moreover, it is studied if some specific 
interactions such as ion pairing, between these drug molecules and an additive X could 
be revealed with a C18-HPLC-system by adding increasing amount of the additive X 
into the eluent. 
 
Ophthalmic pharmaceuticals 1e and 2e are isopropyl ester prodrugs. They are 
hydrolyzed by esterases in the cornea to corresponding acids 1a and 2a which are 
biologically active. The prodrugs themselves are lipophilic, but the biologically active 
acid forms are hydrophilic. Due to the low water solubility, some solubilizing additives 
must be added to the aqueous eye drop formulations in order to dissolve the isopropyl 
ester prodrugs. Pharmacokinetic studies in animals have suggested that a common 
ophthalmic drug solubilizing additive X increases the bioavailability of prodrug 1e by 
increasing its aqueous humor concentration after topical administration (Santen Oy). 
Additive X is a primary amine and exists in physiological pH in cationic form, while 
acid 1a is assumed to exist in anionic form respectively. Thus, ion pair formation 
between these oppositely charged moieties has been suggested. It is assumed that ion-
pair formation might increase the lipophilicity of acid 1a and therefore explain its 
enhanced corneal permeability. On the other hand, additive X might have some other 
specific interaction with ester form which decreases the lipophilicity of prodrug 1e. It 
also cannot be excluded that additive X affects the biological structure of corneal 
surface. Thus, the first aim of this study was to find out if assumed ion-pairing between 
acid form 1a and additive X could be verified as an increased retention time by RP-
HPLC instrument when adding additive X into the eluent.  
 
Another isopropyl ester prodrug 2e is structurally very similar with 1e. It is as well 
hydrolyzed in the cornea to biologically active acid 2a. Therefore it’s possible that 2a 
forms ion pair with additive X as well. Thus, another aim of the study was to find out if 
similar chemical interaction between additive X and acid 2a can be observed by RP-
HPLC as in case of acid 1a. 
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9.2. Materials and methods 
9.2.1. Buffer preparations 
Acetate buffer solution (AcOH) was prepared by mixing desired volume of glacial 
acetic acid with Milli-Q water. Sodium phosphate buffer (SPB) solutions were prepared 
by dissolving required amount of disodium hydrogen phosphate dodecahydrate in Milli-
Q water and adjusting the pH with 8,5 % phosphoric acid solution. Measurements in 
which drug–additive interactions were studied, additive was dissolved in buffer solution 
before pH adjustment. Modified Britton–Robinson buffer (Britton & Robinson 1931) 
was used as universal buffer for pH dependence studies. It was prepared by adding 
equal volumes of 1 M phosphoric acid, 1 M boric acid and 1 M acetic acid into Milli-Q 
water in order to bring the final concentration of each acid to 0,02 M. The desired pH 
was adjusted by addition of 1 M sodium hydroxide solution. 
9.2.2. pH measurements 
Buffer and HPLC eluent pHs were measured by Mettler Toledo MA 235 pH/Ion 
Analyzer. Electrode was calibrated against aqueous buffers using four-point calibration. 
Since there are different pH scales that are employed in pH measurement of HPLC 
mobile phases, henceforward measured pH values are represented as either pHww  or 
pHsw  according to the IUPAC nomenclature (Inczédy et al. 1998). pHww refers to the pH 
value of an aqueous portion of the mobile phase before the addition of acetonitrile 
(MeCN) and pHsw refers to the pH value of a hydro-organic mobile phase measured 
after the addition of acetonitrile respectively.   
9.2.3. HPLC instrumentation and settings 
HPLC analyses were performed with Waters 2695 Alliance Separations Module 
equipped with a Waters 2996 Photodiode Array Detector (Waters Corporation, US) 
using Empower2 Chromatography Data Software  for instrument control and data 
acquisition and processing. Phenomenex-Gemini C18 column (150 x 2,1 mm i.d.; 3 μm) 
was chosen for analyses due to its low free silanol activity, extended pH stability (over 
pH range 1-12) and minimum eluent consumption. In most analyses column was 
equipped with a Phenomenex security guard column. Injection volume of the samples 
was 20 μl. Eluent flow rate was set at 0,15 ml/min while guard column was used and 
0,20 ml/min without it respectively. Retention times tr were measured at least duplicate 
and they were converted into retention factors k by applying Equation 12 in order to 
cancel out the effect of different flow rates. Void volume time t0 was determined by 
uracil. All analyses were performed in room temperature and the column was stabilized 
for at least 30 minutes before analyses. The detection wavelength was set at 215 nm. 
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Before HPLC-studies aqueous mobile phases were filtrated trough 0,45 μm HATF 
mixed cellulose ester membrane filter (Millipore). Hydro organic mobile phases were 
filtrated trough 0,45 μm HVLP Durapore membrane filter (Millipore). Additionally, all 
mobile phases were degassed by ultrasonicator before use. Samples were dissolved in 
20 % acetonitrile solutions. Sample concentrations are presented in Table 1. 
 
Table 1. Sample concentrations of prodrugs (1e and 2e) and acid forms (1a and 2a). 
 
concentrations [μg/ml] 
  1a 2a 1e 2e 
Mixed sample of all drugs (1a, 2a, 1e, 2e) 5,1 6,0 6,3 6,3 
Mixed sample on acid forms (1a, 2a) 10,1 12,0 
Mixed sample of ester forms (1e, 2e) 12,6 12,5 
 
9.3. Results and discussion  
9.3.1. Method development and eluent optimization 
Lipophilicity studies of two commercial isopropyl ester prodrugs (1e and 2e) and their 
biologically active metabolites (1a and 2a) began with HPLC method development. 
Eluent optimization was started by modification of an existing HPLC/MS/MS method 
(Santen Oy) of 2a and 2e (see eluent 1 in Table 2). As was assumed, all compounds 
were separated well (R > 2) and eluted in less than 9 minutes. However, since the aim of 
this study was to mimic ophthalmic drug formulations, eluent pH should be as close to 
neutral pH as possible. Therefore, acetic acid was replaced by sodium phosphate buffer 
( pHww 6,99) as an aqueous phase. The increase of eluent pH however decreased the 
retention of acid forms due to ionization (see eluent 2 in Table 2). Some peak tailing 
was also observed. Hydrophilic acid forms did not retain and separate enough despite 
that the eluent strength was decreased down to 40:60 MeCN/phosphate buffer. At the 
same time, such a weak eluent strength increased retention times and broadened peaks 
of more lipophilic ester forms. Additionally, eluent flow rate could not be increased due 
to the high back pressure of the HPLC instrument. Thus, simultaneous separation of all 
four components was not possible in reasonable run time by isocratic method. Applying 
gradient run on the other hand would have complicated subsequent studies and 
conclusions. Therefore separate isocratic methods were developed for acid and ester 
forms. The most suitable eluent compositions for both methods are highlighted in Table 
2. Minimum criteria for these methods were good resolution (R > 2), reasonable run 
time (less than 10 minutes) and a sufficient retention.  
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Table 2. Retention factors of 1a, 2a, 1e and 2e at different eluent compositions. The 
most suitable eluent compositions for both acid (1a and 2a) and ester (1e and 2e) forms 
are highlighted. 
   Retention factors, k  
Eluent pH 1a 2a 1e 2e Resolution 
60 : 40 MeCN / 0,1 % AcOH 3,82 1 0,55 0,88 2,05 3,48 2,4 / 8,5 / 8,8 
60 : 40 MeCN / SPB 6,99 2 0,16 0,26 1,95 3,29 < 1 / 11,4 / 8,1 
50 : 50 MeCN / SPB 6,99 2 0,21 0,39 4,28 8,47 1,2 / 22,5 / 16,2 
40 : 60 MeCN / SPB 6,99 2 0,38 0,79 14,18 33,90 2,8 / 41,3 / 23,8 
70 : 30 MeCN / SPB 6,99 2     1,09 1,59 3,7 
65 : 35 MeCN / SPB 6,99 2     1,42 2,22 5,4 
60 : 40 MeCN / SPB 6,99 2     1,94 3,27 8,0 
40 : 60 MeCN / SPB 6,99 2 0,39 0,79     2,8 
35 : 65 MeCN / SPB 6,99 2 0,66 1,52     - 
30 : 70 MeCN / SPB 6,99 2 1,33 3,52     10,5 
 
9.3.2. Lipophilicity estimates 
As a by-product of eluent optimization log k values were calculated from determined 
retention factors. The relationship between log k and the volume fractions of organic 
solvent acetonitrile in mobile phase ϕ  appeared to be almost linear for ester forms 1e 
and 2e (see Figure 14) but for acid forms 1a and 2a linear approximation did not 
correlate as well (see Figure 15).  
 
 
Figure 14. Log k values of ester forms 1e and 2e as a function of volume fractions of 
organic solvent in mobile phase ϕ . 
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Figure 15. Log k values of acid forms 1a and 2a as a function of volume fractions of 
organic solvent in mobile phase ϕ . 
 
As was represented in chapter 7.4, log k values are lipophilicity indices on their own, 
but log k values can be extrapolated to pure water log kw values to obtain more 
comparable lipophilicity indices. Hence, log kw values for each molecule were 
determined from their graphs at the points where the lines intersect with y-axis. Another 
lipophilicity parameter, chromatographic hydrophobicity index ϕ 0  was obtained at the 
points where the lines intersect with x-axis respectively (log k = 0). Extrapolated pure 
water log kw and ϕ 0  values are represented in Table 3.  
 
Table 3. Extrapolated pure water log kw and ϕ 0  values of 1a, 2a, 1e and 2e. 
 
  1a 2a 1e 2e 
log kw 0,90 1,48 2,56 3,22 
ϕ0 30,0 41,0 69,2 73,0 
 
According to these HPLC-measurements increasing lipophilicity order of the studied 
molecules is expected to be 1a < 2a < 1e < 2e. Results correlate well with lipophilicity 
parameters (log Pow) obtained from in-house documents (Santen Oy). 
9.3.3. pH-lipophilicity profiles 
The pH-lipophilicity profiles of two commercial isopropyl ester prodrugs (1e and 2e) 
and their biologically active acid metabolites (1a and 2a) were determined from series 
of isocratic measurements at different pH of the eluent. Examples of the obtained 
chromatograms are presented in Figure 24 (see Appendix 1). Retention times were 
converted into log k values and plotted as a function of pH. Ester forms were analyzed 
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by using acetonitrile/universal buffer 65:35 as mobile phase, whereas acid forms were 
analyzed by using acetonitrile/universal buffer 30:70. For acid metabolites (1a and 2a) 
pH-lipophilicity profiles are presented in Figure 16.  
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Lipophilicity as log k of acid forms 1a (A) and 2a (B) versus (♦) pHww and 
(▲) pHsw  using acetonitrile/universal buffer 30:70 as mobile phase. 
 
For acidic components, increasing the pH of the aqueous portion of the mobile phase 
from 2,5 to 8 decreased the retention. At aqueous mobile-phase pHww  values greater 
than 7, both acidic components were in their ionized form. At mobile phase pHww values 
of 4 and lower, the acids exhibited a high retention and lipophilicity, since they were in 
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neutral form. According to these measurements, ionization constant pKa of both acids 
should be close 5 as the most dramatic decreased in retention occurred at the pHww  
region from 4 to 6. However, it’s important to bear in mind that the addition of organic 
solvent to the eluent affects both the pH of the eluent and the ionization event of weak 
acids. Thus, the evaluation of pKa values by RP-HPLC is not completely accurate, but 
gives rough estimates. 
 
For isopropyl ester prodrugs (1e and 2e) pH-lipophilicity profiles are presented in 
Figure 17. As was to be expected, alteration of eluent pH did not affect the retention of 
ester forms significantly since they do not contain any ionizable moieties. 
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Figure 17. Lipophilicity as log k of ester forms 1e (A) and 2e (B) versus (♦) pHww  and 
(▲) pHsw  using acetonitrile/universal buffer 65:35 as mobile phase. 
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9.3.4. Drug-additive interaction studies by RP-HPLC 
Additive X is a primary amine that exists in physiological pH in cationic form while 
acids 1a and 2a exist in anionic form respectively. Therefore ion-pair formation 
between these oppositely charged moieties has been suggested. In this study ion-pairing 
theory was tested by adding increasing amount of additive X into mobile phase. If 
strong ion-pairing would happen, lipophilicity of the acid forms 1a and 2a should be 
improved which could be observed in RP-HPLC measurements as increased retention 
times. 
 
Retention times of acid forms 1a and 2a were analyzed by using acetonitrile/sodium 
phosphate buffer 30:70 as a mobile phase. Desired amount of additive X was dissolved 
in buffer solution before adjusting the pH with 8,5 % phosphoric acid solution to 7,00 ± 
0,02. Day-to-day variation in test conditions was taken into account by performing 
baseline measurements without additive X every day, five times all together. Retention 
times and retention factors are presented in Table 4.  
 
Table 4. Retention times tr and retention factors k of acids 1a and 2a in different 
concentrations of additive X in mobile phase. Retention times without additive X were 
measured five times. Sample concentrations of 1a and 2a were 10,1 μg/ml and 12,0 
μg/ml respectively. 
tr (min) k 
c (additive X) in mobile phase 1a 2a 1a 2a 
0 mM 5,75 ±  0,15 12,76 ± 0,50 2,46 ±  0,09 6,69 ±  0,30 
0,5 mM 5,66 12,50 2,41 6,53 
1 mM 5,67 12,57 2,42 6,57 
10 mM 5,63 12,46 2,39 6,51 
25 mM 5,87 13,30 2,54 7,01 
 
Results do not indicate any apparent dependence on retention times and the amount of 
additive added to the eluent. Slight changes in retention times after the addition of 
additive X into eluent are most likely related to the day-to-day variation in measurement 
conditions. The range of the shortest to the longest retention time is the same with and 
without additive X. The results suggest that either the ion-pair formation does not occur 
or the HPLC method is not sensitive enough to indicate the formation of an ion pair. It 
is also possible that the concentration of additive X should have been significantly 
increased in the eluent so that the results would have been noticeable. The slight 
increase in retention times as the concentration of additive X was increased up to 25 
mM may refer to this. 
 
Since the HPLC method failed to confirm that additive X improves the lipophilicity of 
acid forms 1a and 2a by ion-pairing, it was decided to test whether the HPLC method 
could be used to determine if additive X directly affects the retention of the ester forms. 
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It was assumed that additive X might have some other specific interaction with ester 
forms which could decrease lipophilicity of prodrugs 1e and 2e.  
 
Retention times of ester forms 1e and 2e were analyzed by using acetonitrile/sodium 
phosphate buffer 65:35 as mobile phase. Desired amount of additive X was dissolved in 
buffer solution before adjusting the pH with 8,5 % phosphoric acid solution to 7,45 ± 
0,02. Measured retention times and retention factors are presented in Table 5.  
 
Table 5. Retention times tr and retention factors k of prodrugs 1e and 2e in different 
concentrations of additive X in mobile phase. Sample concentrations of 1e and 2e were 
12,6 μg/ml and 12,5 μg/ml respectively. 
 
tr (min) k 
c (additive X) in mobile phase 1e 2e 1e 2e 
0 mM 6,41 8,64 1,43 2,27 
5 mM 6,42 8,66 1,43 2,28 
25 mM 6,32 8,45 1,39 2,20 
 
 
Also, in case of ester forms, the addition of additive X to the eluent did not significantly 
affect the retention times. With the highest additive concentration (25 mM) the retention 
times for both 1e and 2e were slightly shorter, but the difference may also be due to 
measurements made on different days. Nevertheless, minor shortening in retention times 
may indicate that the additive has some interaction with isopropyl ester prodrugs 1e and 
2e which decreases their lipophilicity. The results could have been verified by using 
higher eluent concentrations. 
 
According to these drug-additive studies by HPLC it cannot be confirmed that the 
additive X would affect the lipophilicity of isopropyl ester prodrugs 1e and 2e or their 
active acid forms 1a and 2a. It is possible that additive X does not interact with the drug 
molecules but affects the biological structure of the corneal surface and thus improves 
the permeation of these drugs.  
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10. DIRECT LOG POW MEASUREMENTS 
10.1. Background and purpose of the study 
Formulation development at Santen Oy has mainly relied on lipophilicity parameters 
obtained from literature or supplied by ingredient manufactures. However, the 
availability of octanol-water partition coefficients (log Pow) is quite poor and parameters 
are often rough estimates. Thus, developing in-house laboratory models to determine 
octanol-water partition coefficients could improve the formulation development. 
 
In this chapter, a modified shake-flask method is set up for determining direct log Pow 
values of drugs at Santen Oy. In order to decrease required amount of drug molecules, 
the traditional shake-flask method described earlier in chapter 6.2 was modified into 
small-scale. The main target of the method development was to determine the time 
required in achieving partition equilibrium. Hence, partition experiments were 
performed by applying different shaking times varying from 15 minutes to 180 minutes. 
Duplicate determinations were made for each time points. Method was validated by 
determining octanol-water partition coefficient for isopropyl ester prodrug 2e at 
physiological pH, since its log Pow value was known to be 4,5 at pH 7. Additionally, 
lipophilicity (log Pow) of prodrug 2e with additive X was directly measured by this 
method in order to compare results obtained in previous chapter by RP-HPLC method. 
10.2. Development and validation of modified shake-flask 
method 
 
Before octanol-water partition experiments aqueous buffer phase and organic n-octanol 
phase were pre-saturated with each others.  A sodium phosphate buffer solution (13 
mM) was prepared by diluting 0,36 g sodium dihydrogenphosphate dodecahydrate in 
100 ml of distilled water and adjusting the pH of the buffer to 6,96 by adding 0,22 ml of 
aqueous 8,5 % H3PO4. Equal amounts of above sodium phosphate buffer and n-octanol 
were mixed in eluent bottle and stirred vigorously by magnetic stirrer for 18 hours to 
mutually saturate them. Phases were separated in separatory funnel.  
 
Schematic presentation of developed modified shake-flask method for determining 
direct log Pow value of prodrug 2e is presented in Figure 18. Accurately 1 ml of stock 
solution of prodrug 2e in acetonitrile (61 μg/ml) was pipetted to 10 ml disposable 
centrifuge tube and the solvent was evaporated by nitrogen evaporator in 30 minutes at 
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22 °C, after which 2 ml of pre-saturated n-octanol was added to it. Solution was 
sonicated for 15 minutes to ensure the complete solvation of prodrug 2e into n-octanol. 
An equal volume of pre-saturated aqueous buffer phase was then added and the mixture 
was shaken for a sample specific time (15, 30, 60, 120 or 180 minutes) by a multitube 
vortexer at room temperature. Shaking speed was adjusted as powerful as possible, 
however preventing solvents from reaching the cap of the centrifuge tube. In order to 
separate organic and aqueous phases properly, samples were centrifuged for 10 minutes 
at 2000 rpm. 
 
Concentration of prodrug 2e in both phases was determined by HPLC/MS/MS using 
already existing internal standard method (Santen Oy). Phase separation and sample 
preparations for HPLC-MS analysis were performed as follows: Phases were separated 
completely immediately after centrifugation to avoid the additional partitioning of drug 
molecules. 1 ml of n-octanol phase was pipetted to a 25 ml volumetric flask to wait for 
further treatments and the rest of the n-octanol phase was removed above the aqueous 
phase by a pasteur pipette. Then 1 ml of aqueous phase was mixed with 1 ml of internal 
standard acetonitrile solution (5 ng/ml) in a clean test tube. Since the drug concentration 
of n-octanol phase was assumed to be close to the initial concentration (~30 μg/ml), n-
octanol phase was diluted 10 000 fold in acetonitrile. In order to remove traces of n-
octanol, 1 ml of diluted sample was evaporated by nitrogen evaporator in 30 minutes at 
30 °C. Remaining sample was diluted in 1 ml of internal standard acetonitrile solution 
(5 ng/ml) and 1 ml of Milli-Q water was added. Thus, the final internal standard 
concentration of all samples was 2,5 ng/ml and the diluents contained equal amounts of 
water and acetonitrile.  Concentration of prodrug 2e in both phases was determined by 
HPLC/MS/MS at Santen Oy. 
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  1 ml of 2a stock solution  
 
  evaporation (30 min, 22 °C) 
 
  + 2ml of pre-saturated n-octanol 
 
  15 min sonication (for dissolving 2a into n-octanol) 
 
  + 2ml of pre-saturated aqueous buffer solution 
 
shaking for a sample specific time (15, 30, 60, 120 or 180 min) 
 
sentrifugation (10 min, 2000 rpm) 
 
 
 
1 ml of n-octanol phase    1 ml of aqueous phase 
 
diluted 1/25 with MeCN    +1 ml of internal standard (5 ng/ml) 
 
diluted 1/400 with MeCN    2-fold dilution obtained 
 
1ml of the sample evaporated (30 min, 30 °C) concentration measurement 
 
+1 ml of internal standard (5 ng/ml) 
 
+ 1ml MilliQ-water 
 
20 000-fold dilution obtained 
 
concentration measurement 
 
Figure 18. Schematic presentation of developed modified shake-flask method for 
determining direct log Pow values of drugs at Santen Oy.  
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10.2.1. Results and discussion 
Concentrations of prodrug 2e in both water and octanol phases were determined by 
HPLC/MS/MS from diluted samples. Samples in octanol phase were diluted 20 000-
fold and in water phase 2-fold before concentration measurements. Table 6 presents 
measured concentrations of diluted samples and calculated actual concentrations before 
dilutions. The last column of the table contains approximated sample concentrations in 
octanol phase which has been calculated as a difference between the initial sample 
concentration and the measured sample concentration in water phase. 
 
Table 6. The amount of prodrug 2a measured from diluted samples and calculated 
before dilutions in water cw and n-octanol co phases. Approximated co values were 
calculated as a difference between the initial sample concentration (27489,25 ng/ml) 
and the measured concentration of the water phase. 
 
  diluted samples undiluted samples approximated 
tshaking [min] cw [ng/ml] co [ng/ml] cw  [ng/ml] co [ng/ml] co [ng/ml] 
15 0,50695 0,00000 1,01 0,00 27488,24 
15 0,45068 1,43751 0,90 28750,20 27488,35 
30 0,43635 1,40288 0,87 28057,60 27488,38 
30 0,45669 1,36431 0,91 27286,20 27488,34 
60 0,42825 1,50994 0,86 30198,80 27488,39 
60 0,79700 1,41264 1,59 28252,80 27487,66 
120 0,40962 1,49566 0,82 29913,20 27488,43 
120 0,43925 1,33584 0,88 26716,80 27488,37 
180 0,40829 1,41042 0,82 28208,40 27488,43 
180 0,45451 1,38397 0,91 27679,40 27488,34 
 
 
Octanol-water partition coefficients log Pow were calculated by equation 10 from actual 
undiluted sample concentrations. For each shaking time the average log Pow was 
calculated. Two measurements were excludes from calculations due to sample 
contamination (line 6 in Tables 6 and 7) and instrumental error (line 1 in Tables 6 and 
7). Additionally approximated log Pow values were calculated by using approximated co 
values. Octanol-water partition coefficients log Pow are presented in Table 7. 
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Table 7. Calculated octanol-water partition coefficients log Pow  of prodrug 2e. 
 
tshaking [min] log Pow mean log Pow (appr.) mean 
15 -  4,43  
15 4,50 4,50 4,48 4,46 
30 4,51  4,50  
30 4,48 4,49 4,48 4,49 
60 4,25  4,24  
60 4,55 4,55 4,51 4,51 
120 4,56  4,53  
120 4,48 4,52 4,50 4,51 
180 4,54  4,53  
180 4,48 4,51 4,48 4,50 
 
 
Obtained log Pow values correspond very well with the initial data according to which 
octanol-water partition coefficient for isopropyl ester prodrug 2e is 4,5 at pH 7. At least 
for this substance, shaking time does not seem to have any effect on the result. Even 15 
minutes of shaking might be accurate enough. However, with only one test substance it 
is not possible to draw general conclusions about the appropriate shaking time. 
 
A particularly useful finding it that the approximated log Pow values correspond well to 
the measured values. This enables to measure drug concentration only from the aqueous 
phase which would speed up the process and reduce the use of solvents because the 
dilutions of the octanol phase would not be needed. Additionally, this modified small-
scale system consumes less solvent than the traditional shaking-flask method. 
 
The main challenge of the method is the need of background information on the 
lipophilicity of the substance. Lipophilicity estimates help to designate which of the 
phases should be used for concentration measurements and how to design appropriate 
dilutions if needed. 
10.3. Modelling drug-additive interactions by modified 
shake-flask method 
Modified shake-flask method developed in previous chapter 10.2 was tested also for 
drug-additive interaction studies. Lipophilicity (log Pow) of prodrug 2e with increasing 
amount of additive X was determined by this method in order to compare results 
obtained in previous chapter by RP-HPLC method. Octanol-water partitioning 
experiments were performed otherwise like in chapter 10.2 except that the variating 
amount of additive X was added to the aqueous sodium phosphate buffer phases and the 
pH was adjusted to 6,98 ± 0,04. Triplicated determinations were made for each additive 
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concentration. Samples were shaken for 40 minutes. Drug concentrations were 
measured only in aqueous phase and concentrations in n-octanol phase were 
approximated by calculating the difference between the initial sample concentration 
(27489,25 ng/ml) and the measured drug concentrations in the water phase. 
 
10.3.1. Results and discussion 
The partition results (presented in Table 8) indicate that as the amount of additive X 
increases the lipophilicity (log Pow) of the prodrug 2e is also increased. Growth was 
almost linear, but there was also some deviation between the samples. Standard 
deviation between the samples is illustrated in Figure 19 by vertical line segments.   
 
Table 8. Measured drug concentrations in aqueous phase cw and calculated drug 
concentrations in octanol phase co. The increasing amount of additive X is presented as 
a mass ration between additive X and prodrug 2e in fist column of the table.  
 
mX/m2e cw [ng/ml] co (appr.) [ng/ml] Pow Pow (avr.) log Pow log Pow (avr.) 
0 1,0523 27488,1977 26123,01 4,42 
0 0,9638 27488,2862 28520,74 4,46 
0 0,8983 27488,3517 30601,10 28414,95 4,49 4,45 
3,5 0,9709 27488,2791 28312,16 4,45 
3,5 0,9514 27488,2986 28893,08 4,46 
3,5 0,9194 27488,3306 29899,42 29034,89 4,48 4,46 
17,5 0,8799 27488,3701 31240,33 4,49 
17,5 1,1224 27488,1276 24490,06 4,39 
17,5 0,8618 27488,3882 31897,22 29209,20 4,50 4,46 
35 0,8770 27488,3730 31342,93 4,50 
35 0,9542 27488,2958 28807,08 4,46 
35 0,9312 27488,3188 29519,24 29889,75 4,47 4,48 
52,5 0,9013 27488,3487 30499,91 4,48 
52,5 0,9374 27488,3126 29323,37 4,47 
52,5 0,9122 27488,3378 30135,43 29986,24 4,48 4,48 
70 0,8080 27488,4420 34021,19 4,53 
70 0,8545 27488,3955 32167,48 4,51 
70 0,8333 27488,4167 32987,42 33058,70 4,52 4,52 
350 0,6675 27488,5825 41183,87 4,61 
350 0,7784 27488,4716 35314,98 4,55 
350 0,6637 27488,5863 41415,94 39304,93 4,62 4,59 
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Figure 19. Lipophilicity (log Pow) of the prodrug 2e as a function of increasing amount 
of additive X expressed as mass ration between additive X and prodrug 2e. 
 
Obtained results do not correlate with earlier RP-HPLC measurement which indicated 
that additive X either does not affect at all or slightly decreases the lipophilicity of 
prodrug 2e. 
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11. VALIDATION OF RP-HPLC METHOD FOR 
DRUG-ADDITIVE ION-PAIR FORMATION 
11.1. Background 
In this chapter, the usefulness of the C18-HPLC method for studying drug-additive 
interactions was put to the test. In chapter 9.3.4 assumed ion-pairing between acid form 
1a and additive X could not be verified as an increased retention time by RP-HPLC. At 
that time, it remained unclear whether the developed RP-HPLC method was not 
sensitive enough to detect ion-pairing or if ion-pair formation did not occur at all 
between acid form 1a and additive X. Hence, it was decided to test the RP-HPLC 
method again, this time with substances that are already known to form ion pair. 
 
 
 
Figure 20. Chemical strictures of timolol and potassium sorbate. 
 
Method was validated by using common anti-glaucoma drug timolol and sorbate 
additive, for which ion pairing had been previously verified by NMR (Higashiyama et 
al. 2007). Amino group in the tertiary butylaminopropanol moiety of timolol exists in 
physiological pH in cationic form while sorbate is anionic respectively. Sorbate is 
known to improve the bioavailability of timolol by increasing its ocular penetration due 
to the increased partitioning of timolol into the corneal epithelium. (Higashiyama et al. 
2004)  In this study ion-pairing between timolol and sorbate was studied by a RP-HPLC 
instrument by adding increasing amount of potassium sorbate into the eluent. Before ion 
pairing studies eluent composition was optimized for timolol. Additionally the pH-
lipophilicity profile of timolol was measured.  
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11.2. Materials and methods 
11.2.1. Buffer preparations 
Sodium phosphate buffer solutions were prepared by dissolving required amount of 
disodium hydrogen phosphate dodecahydrate in Milli-Q water and adjusting the pH to 
7,00 with 8,5 % phosphoric acid solution. Studies in which ion-pair formation between 
timolol and sorbate was investigated, potassium sorbate was dissolved in buffer solution 
and stirred for 10 minutes by magnetic stirrer before pH adjustment (pH 7,00 ± 0,01). 
Modified Britton–Robinson buffer (Britton & Robinson 1931) was used as universal 
buffer for the pH dependence studies. It was prepared by adding equal volumes of 1 M 
phosphoric acid, 1 M boric acid and 1 M acetic acid into Milli-Q water in order to bring 
the final concentration of each acid to 0,02 M. The desired pH was adjusted by addition 
of 1 M sodium hydroxide solution. 
11.2.2. pH measurements 
Buffer and HPLC eluent pHs were measured by Mettler Toledo MA 235 pH/Ion 
Analyzer. Electrode was calibrated against aqueous buffers using four-point calibration. 
In pH dependence studies the pH of the mobile phases were measured both before and 
after the addition of acetonitrile. pHww refers to the pH value of an aqueous portion of 
the mobile phase before the addition of acetonitrile (MeCN) and pHsw refers to the pH 
value of a hydro-organic mobile phase measured after the addition of acetonitrile 
respectively.   
 
11.2.3. HPLC instrumentation and settings 
HPLC analyses were performed with Waters 2695 Alliance Separations Module 
equipped with a Waters 2996 Photodiode Array Detector (Waters Corporation, US) 
using Empower2 Chromatography Data Software  for instrument control and data 
acquisition and processing. Phenomenex-Gemini C18 column (150 x 2,1 mm i.d.; 3 μm) 
was equipped with a Phenomenex security guard column. Eluent flow rate was set at 
0,15 ml/min. Injection volume of the samples was 10 μl. Retention times tr were 
measured at least triplicate and they were converted into retention factors k by applying 
Equation 12 in order to cancel out the effect of different flow rates. Void volume time to 
was determined by uracil. All analyses were performed in room temperature and the 
column was stabilized for at least 30 minutes before analyses. The detection wavelength 
was set at 294 nm. 
 
Before HPLC-studies aqueous mobile phases were filtrated trough 0,45 μm HATF 
mixed cellulose ester membrane filter (Millipore). Hydro organic mobile phases were 
filtrated trough 0,45 μm HVLP Durapore membrane filter (Millipore). Additionally all 
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mobile phases were degassed by ultrasonicator before use. Timolol hemihydrate 
samples were dissolved in 1 % methanol solutions. Sample concentrations were 20 
μmol/l. 
11.3. Results and discussion  
11.3.1. Eluent optimization and lipophilicity estimates for timolol 
hemihydrate 
Six different mobile phase compositions were tested for timolol hemihydrate to achieve 
sufficient retention in reasonable run time for further studies. The most suitable eluent 
composition 25:75 MeCN/sodium phosphate buffer is highlighted in Table 9. 
 
Table 9. Retention times tr, retention factors k and log k of timolol hemihydrate at 
different eluent compositions (to = 2,64 min). The most suitable eluent composition is 
highlighted. 
Eluent tr [min] k log k 
45:65 MeCN / sodium phosphate buffer 3,28 0,24 -0,62 
40:60 MeCN / sodium phosphate buffer 3,46 0,31 -0,51 
30:70 MeCN / sodium phosphate buffer 4,28 0,62 -0,21 
25:75 MeCN / sodium phosphate buffer 5,39 1,04 0,02 
20:80 MeCN / sodium phosphate buffer 8,18 2,10 0,32 
15:85 MeCN / sodium phosphate buffer 16,96 5,42 0,73 
 
As a by-product of the eluent optimization several lipophilicity estimates were 
determined. Log k values were calculated from retention factors and plotted versus the 
volume fractions of the organic solvent acetonitrile in mobile phase ϕ.  Linear 
approximation appeared to be quite poor (see Figure 21).  
 
Figure 21. Log k values of timolol hemihydrate as a function of volume fractions of 
organic solvent in mobile phase ϕ. 
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Pure water log kw and chromatographic hydrophobicity index ϕ0  values extrapolated 
from the intersections of the axes are presented in Table 10. Obtained lipophilicity 
estimate values for timolol are not useful alone, but can be used in the future if the 
lipophilicity of timolol and other substances needs to be compared. 
 
Table 10. Extrapolated pure water log kw and chromatographic hydrophobicity index 
ϕ0  values. 
  log kw ϕ0 
Timolol hemihydrate 1,21 28,2 
 
11.3.2. pH-lipophilicity profile of timolol hemihydrate 
HPLC retention of timolol, expressed as log k, was monitored as a function of pH using 
acetonitrile/universal buffer 25:75 as a mobile phase. The analysis was performed as in 
the chapter 9.3.3. The examples of the measured chromatograms are presented in Figure 
25 (see Appendix 1) and the obtained pH-lipophilicity profile is presented in Figure 22. 
Increasing the pHww  of the aqueous portion of the mobile phase from 2,5 to 10,7 
enhanced retention and lipophilicity of timolol. At mobile phase pHww  values 11 and 
greater timolol exhibited high retention which indicates that timolol was in neutral form. 
However, as the pHww was adjusted to below 7, timolol eluted close to the void volume 
since it was in ionized form. According to these measurements, ionization constant pKa 
of timolol hemihydrate should be close to 9 as the most dramatic decreased in retention 
occurred at the pHww  region from 8 to 10. Considering the corresponding pKa value 9,2 
reported in literature (Sutinen et al. 2000), obtained estimate is pretty good. 
 
 
Figure 22. Lipophilicity as log k of timolol hemihydrate versus (♦) pHww and (▲) pHsw  
using acetonitrile/universal buffer 25:75 as mobile phase. 
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11.3.3. HPLC analysis of ion-pair formation between timolol and sorbate 
In this study ion-pairing between timolol and sorbate was studied with RP-HPLC by 
adding increasing amount of potassium sorbate into the eluent. Ion-pairing should 
improve the lipophilicity of timolol which supposedly could be observed in RP-HPLC 
measurements as increased retention times. Retention times of timolol were analyzed by 
using acetonitrile/sodium phosphate buffer 25:75 as mobile phase. Desired amount of 
potassium sorbate was dissolved in buffer solution before adjusting the pH with 8,5 % 
phosphoric acid solution to 7,00 ± 0,01. The examples of the obtained chromatograms 
are presented in Figure 26 (see Appendix 1). Measured retention times and retention 
factors are presented in Table 11. 
 
Table 11. Retention times t0, retention factors k and log k of timolol in different 
concentrations of potassium sorbate in mobile phase (t0 = 2,64 min). Sample 
concentration of timolol was 20 μmol/l. 
csorbate (mM) tr (min) k  log k 
0,0 5,48 1,07 0,03 
1,0 5,70 1,16 0,06 
2,5 6,11 1,31 0,12 
5,0 6,41 1,43 0,15 
7,5 6,78 1,57 0,20 
10,0 6,95 1,63 0,21 
15,0 7,35 1,78 0,25 
 
Results indicate clear dependence on retention times and the amount of sorbate added to 
the eluent (see Figure 23). Increasing sorbate concentration in mobile phase increases 
significantly the retention of timolol. The results suggest that RP-HPLC is able to 
indicate ion-pair formation. 
  
Figure 23. Lipophilicity (log k) of timolol as a function of increasing amount of sorbate 
added to the mobile phase expressed as log csorbate.  
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12. CONCLUSIONS 
In this thesis various models for drug permeation studies were reviewed. The emphasis 
was on the determination of physicochemical parameters such as lipophilicity, 
expressed as logarithm of octanol-water partition constant (log Pow), and ionization 
constant pKa. These properties have a huge impact on membrane permeability and they 
can be used to predict drug absorption. Physicochemical analysis methods are attractive 
because they predict passive drug permeation reproducibly and efficiently. These 
methods also have a great high throughput potential and they require less resources and 
manpower compared to many other in vitro permeability prediction methods. On the 
other hand, they do not take into account physiological conditions or any specific 
interactions between drugs and membrane, unlike cell culture and tissue based models. 
However, physicochemical parameters can be used to select the most potential drug 
candidates for further animal studies and clinical trials on humans. They also give 
valuable information for formulation development.  
 
Experimental part of this thesis was performed in the Quality Control and Analytical 
Development Laboratory of Santen Oy. The aim of the study was to develop in-house 
physicochemical laboratory models to support ophthalmic formulation development at 
Santen Oy. The main idea for experimental study was to find out if common RP-HPLC 
instruments and a simple shake-flask method could be utilized in modelling the 
lipophilicity of the ophthalmic drugs. The first goal was to find out how the effect of the 
formulation pH could be studied by HPLC. Another aim was to test whether the HPLC 
measurements or the shake-flask method could reveal drug-additive interaction. 
 
Experimental work consisted of three parts. In the first part, lipophilicity of two 
commercial isopropyl ester prodrugs (1e and 2e) and their biologically active 
metabolites (1a and 2a) were studied by HPLC. Measurements consist of eluent 
optimization, lipophilicity estimation, pH-lipophilicity profile measurements and drug-
additive interaction studies. As a by-product of the eluent optimization several 
lipophilicity estimates were determined. According to them the lipophilicity order of the 
studied molecules was expected to be 1a < 2a < 1e < 2e, which correlate well with 
reported lipophilicity parameters (log Pow). Thus, it seems like a common C18-HPLC 
instrument can be utilized for comparing the lipophilicity of structurally similar drugs.  
 
The pH-lipophilicity profiles of drugs 1a, 2a, 1e and 2e were determined from the series 
of isocratic measurements at different pH of the eluent. As was expected, changes in pH 
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did not affect the retention of the ester forms 1e and 2e significantly since they do not 
contain any ionizable moieties. For the acid forms 1a and 2a obtained pH-lipophilicity 
profiles suggested that the ionization constant pKa for both acids is close to 5. Because 
the addition of organic solvent to the eluent affects both the pH of the eluent and the 
ionization event of weak acids, the evaluation of pKa values by RP-HPLC is not 
completely accurate.  
 
One of the main goals of this study was to find out of if some specific interactions, such 
as ion pairing between drug molecules and drug additives could be revealed with C18-
HPLC-system. Pharmacokinetic studies in animals have suggested that cationic 
ophthalmic drug additive X increases the bioavailability of prodrug 1e. Three different 
hypotheses had been made to explain the improved corneal permeability: 
 
1) Additive X forms ion-pair with acid metabolite 1a which increases the lipophilicity 
of acid 1a. 
2) Additive X might have some other specific interaction with ester prodrug 1e which 
decreases lipophilicity of prodrug 1e.  
3) Additive X affects the biological structure of corneal surface.  
 
Thus, it was studied if drug-additive interaction could be verified as changes in retention 
times by a RP-HPLC instrument when adding additive X into the eluent. Ion-pairing 
between acid forms (1a, 2a) and additive X could not be verified as an increased 
retention time by RP-HPLC. Additive X either did not affect at all or slightly increased 
the lipophilicity of acid forms. For the ester forms, the results were analogous. Additive 
X either did not affect or slightly decreased the lipophilicity of prodrugs 1e and 2e. 
Using higher eluent concentrations of additive X could have provided more information, 
but due to the high backpressure of the HPLC instrument, the concentration of the 
additive X could not be increased. According to these drug-additive studies, it could not 
be confirmed that the additive X would affect the lipophilicity of the studied drugs. It is 
possible that the additive X does not interact with the drug molecules but affects the 
biological structure of the corneal surface and thus improves the permeation of these 
drugs.  
 
In the second part, a modified shake-flask method was set up for determining octanol-
water partition constants (log Pow values) of drugs at Santen Oy. Traditional shake-flask 
method was modified into small-scale in order to decrease solvent and drug 
consumption. Method was validated by isopropyl ester prodrug 2e for which log Pow 
value was known to be 4,5 at pH 7. Obtained log Pow values 4,52 ± 0,04 and 
approximated log Pow values 4,48 ± 0,05 correspond remarkably well with reference 
data even with only 15 minutes shaking time. Developed method seemed to be accurate 
and reliable enough to be used more extensively in Santen Oy.  
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To compare the results obtained previously by the RP-HPLC method, drug-additive 
interaction was tested also with the shake-flask method by measuring log Pow of prodrug 
2e with additive X. Partition results indicated that as the mass ration between the 
additive X and the prodrug 2e increased the log Pow of the prodrug 2e was also 
increased. Growth was almost linear. Obtained results did not correlate with the earlier 
RP-HPLC measurement which indicated that additive X either does not affect at all or 
slightly decreases the lipophilicity of the prodrug 2e. 
 
Since in the first part of the experimental work it remained unclear whether the 
developed RP-HPLC method was not sensitive enough to detect ion-pairing or if ion-
pair formation did not occur at all between the acid form 1a and the additive X, in third 
part a C18-HPLC method for studying drug-additive interactions was validated by using 
common anti-glaucoma drug timolol and sorbate additive, for which ion pairing had 
been previously verified. Increasing sorbate concentration in mobile phase increased 
significantly the retention of timolol. Enhanced lipophilicity of timolol was assumed to 
occur due to ion pairing with sorbate. Thus, the results suggest that RP-HPLC method is 
able to indicate ion-pair formation between drugs and pharmaceutical additives. This 
further makes hypothesis 1 unlikely for the previously studied 1a-X molecule pairs, as 
ion-pairing should have been detected for them as well. Previously developed pH-
lipophilicity profile measurements were performed also for timolol. Ionization constant 
was estimated to be 9 which correspond well with the pKa value 9,2 reported in 
literature. 
 
In this thesis, it was verified that the lipophilicity order between drugs can be easily 
studied by HPLC. Retention times themselves are good lipophilicity estimates, but by 
measuring the retention factors of the compounds at 3-5 different organic phase 
concentrations, extrapolated pure water log kw and hydrophobicity index ϕ 0 values 
could be also converted into more comparable octanol-water partition coefficients. 
However, it would require calibrating the HPLC-system with compounds for which 
both hydrophobicity index ϕ 0 values and log Pow values are known. 
 
This project succeeded also in developing a rather simple HPLC method for studying 
the ionization of the drugs as a function of pH. Particularly useful findings were the 
Phenomenex-Gemini C18 column with great pH stability and the modified universal 
buffer solution which enabled measurements across a wide pH range. The method 
yielded good pKa estimates, but the results must be treated with caution because the 
addition of organic solvent to the eluent affects both the pH of the eluent and the 
ionization event of the analytes. However, even rough pKa estimates can be useful 
information for drug formulation development. 
 
In addition, it was also demonstrated that the common C18-HPLC instrument can be 
used to reveal interactions between drugs and formulation additives. The ion-pair 
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formation between the drug and the additive can be detected as increased retention 
times when the amount of additive in mobile phase is increased. 
 
Finally, a modified shake-flask method was set up for determining direct log Pow values 
of drugs at Santen Oy. Method was developed by using already existing equipment and 
instruments. Obtained log Pow values were very accurate and repeatable for the used 
reference sample, but the wider deployment of the method would require further testing 
with other reference substances. A particularly useful finding was that the approximated 
log Pow values correspond well to measured values. At least with very lipophilic drugs 
this enables to measure drug concentration only from the aqueous phase which speeds 
up the process and reduce the use of solvents because dilutions of the octanol phase 
would not be needed. The main challenge of this method was the need of background 
information on the lipophilicity of the drug. This is however a very common problem in 
physicochemical analyses. 
 
The main targets of the experimental work were achieved. It was verified that both 
common HPLC instruments and the modified shake-flask method can be utilized in 
modelling the lipophilicity of the ophthalmic drugs. Optimal formulation pH and drug-
additive ion-pairing can be studied by RP-HPLC. Thus Quality Control and Analytical 
Development Laboratory could support ophthalmic formulation development at Santen 
Oy by using models developed in this thesis. However, well-established utilization of 
the models would still require the HPLC-method to be calibrated with reference 
substances so that the measured retention factors could be converted into more 
comparable octanol-water partition coefficients. In addition, it remained unclear in this 
study, why the ophthalmic drug solubilizing additive X increases the bioavailability of 
the prodrug 1e. Defining the mechanism would require further experiments. 
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APPENDIX 1: EXAMPLES OF HPLC 
CHROMATOGRAMS 
 
Figure 24. Retention times of acid metabolites (1a and 2a) determined from series of 
isocratic measurements at different pH of the eluent in chapter 9.3.3.  
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Figure 25. Retention times of timolol hemihydrate (THH) determined from series of 
isocratic measurements at different pH of the eluent in chapter 11.3.2. 
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Figure 26. Retention times of timolol hemihydrate (THH) as increasing amount of 
sorbate was added to the mobile phase in chapter 11.3.3. 
